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EXPERIMENTAL EXECUTION 
Seema K. Shah* 
Abstract: On July 23, 2014, an execution in Arizona lasted nearly two hours, with the 
inmate struggling to breathe and gasping over 600 times, according to a local reporter 
witnessing the execution. This was the third example of a botched execution in seven 
months. The Supreme Court last evaluated the constitutionality of execution by lethal 
injection in 2008, but did not provide a clear standard for evaluating risks. Since that time, 
the lethal injection landscape has transformed. States are using entirely new drugs and drug 
combinations, and sometimes obtain these drugs from questionable sources, making it hard to 
predict what will happen in any given execution. The Court has now granted certiorari to 
examine the constitutionality of Oklahoma’s lethal injection protocol in the case of Glossip v. 
Gross. 
Although it is increasingly common to refer to lethal injection executions as 
experimental, this Article is the first to conduct a rigorous analysis of whether and to what 
extent executions by lethal injection involve the conduct of research and therefore should be 
analyzed under the ethical and regulatory framework that governs biomedical research. I 
argue that an important factor driving this high error rate is that the use of novel drugs, drug 
combinations, and dosages in lethal injection executions is a type of research. More 
specifically, it is poorly designed experimentation that is not based on evidence. If the death 
penalty is justified, individual inmates are being exposed to uncertain (and sometimes 
unnecessary) risks in order to obtain benefits for others by furthering the underlying aims of 
capital punishment. 
This insight suggests three important conclusions. First, states should draw from existing 
scholarship on ethics and regulations that apply to biomedical research with captive and 
vulnerable populations. Prisoners are considered a vulnerable population, and experimental 
executions involving prisoners should abide by the general principles that are applicable to 
research: respect for autonomy, non-maleficence, and justice. Second, legal safeguards that 
follow from these principles should be applied to executions—in particular, states should ask 
for informed consent from prisoners to modifications of lethal injection protocols, obtain 
independent review by a regulatory body like the Food and Drug Administration, and apply a 
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standard requiring risk minimization in the choice of drugs and procedures. Finally, states 
should systematically gather data as they engage in experimental execution. 
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INTRODUCTION 
An execution in Oklahoma went terribly awry on April 28, 2014.1 
Oklahoma was administering a new execution protocol that used the 
drug midazolam, a sedative that is often used in combination with other 
anesthetic agents.2 Oklahoma had never used this drug in executions 
before; in fact, only a few states had any experience with using the drug 
in lethal injections.3 Florida had previously used this drug in lethal 
injections, but with a dose five times higher than what was indicated in 
Oklahoma’s protocol.4 If the execution had gone as planned, Clayton 
Lockett would have first received midazolam; been declared 
1. Helen Pow, Execution Horribly Botched in Oklahoma, DAILY MAIL (Apr. 29, 2014), 
http://www.dailymail.co.uk/news/article-2615631/Oklahoma-prepares-execute-2-inmates.html. 
2. Manufacturer’s Drug Catalog for Midazolam, SAGENT PHARMACEUTICALS (2014), 
http://www.sagentpharma.com/Products/Midazolam/Catalog/Midazolam_Catalog.pdf. 
3. Pow, supra note 1. 
4. Id. 
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unconscious; then received vecuronium bromide (a 
paralytic/neuromuscular blocking agent that would restrict his 
movements); and finally received potassium chloride (the drug likely to 
end his life).5 A few minutes after a prison official declared him 
unconscious, Lockett mumbled statements including the word, “man.”6 
He “began breathing heavily, writhing, clenching his teeth and straining 
to lift his head off the pillow.”7 Prison officials then blocked the 
witnesses from observing the rest of the proceedings.8 The Department 
of Corrections then called off the execution and unsuccessfully tried to 
resuscitate Lockett, and Lockett eventually died of a heart attack 
approximately forty-five minutes after the execution began.9 Although a 
Department of Corrections official stated that Lockett’s veins 
“exploded,”10 an autopsy examination performed by a forensic 
pathologist hired by death row inmates appears to contradict official 
reports.11 Prison officials claimed that they had to inject the drugs into 
Lockett’s femoral vein, located in his groin, which is riskier and more 
difficult than using more common injection sites.12 However, the 
autopsy report contradicts this claim, finding that Lockett’s surface and 
deep veins had “excellent” integrity.13 Another execution scheduled to 
occur that same night was stayed for several months, pending an 
investigation into Mr. Lockett’s execution, but took place on January 15, 
2015.14 Clayton Lockett’s estate has brought suit against the State of 
5. OKLA. STATE PENITENTIARY, OSP 040301-01, PROCEDURES FOR THE EXECUTION OF 
OFFENDERS SENTENCED TO DEATH (2014), available at 
http://bloximages.newyork1.vip.townnews.com/tulsaworld.com/content/tncms/assets/v3/editorial/e/
37/e3763982-d19c-11e3-addc-0017a43b2370/5362fb4c11d06.pdf.pdf; see also State-by-State 
Lethal Injection Information, Oklahoma, DEATH PENALTY INFO. CTR., 
http://www.deathpenaltyinfo.org/state-lethal-injection (last visited Jan. 5, 2015). 
6. Greg Botelho & Dana Ford, Oklahoma Stops Execution After Botching Drug Delivery; Inmate 
Dies, CNN (Oct. 9, 2014, 2:55 PM), http://www.cnn.com/2014/04/29/us/oklahoma-botched-
execution/index.html. 
7. Pow, supra note 1. 
8. Id. 
9. Michael Muskal, Private Autopsy Blames Oklahoma for Botched Execution, L.A. TIMES (June 
13, 2014), http://www.latimes.com/nation/nationnow/la-na-nn-autopsy-botched-oklahoma-
execution-20140613-story.html; Michele Richinick, White House Weighs in on Botched Oklahoma 
Execution, MSNBC (Apr. 30, 2014, 8:23 AM), http://www.msnbc.com/morning-joe/oklahoma-
governor-lockett-botched-execution. 
10. Botelho & Ford, supra note 6 
11. Muskal, supra note 9. 
12. Id. 
13. Id. 
14. Josh Sanburn, Oklahoma Executes First Inmate Since Botched Lethal Injection in April, TIME 
(Jan. 15, 2015), http://time.com/3669126/oklahoma-lethal-injection-execution-charles-warner-
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Oklahoma and a physician alleged to have been involved in the 
execution, claiming violations of the Eighth Amendment to the U.S. 
Constitution, international law, and human decency.15 Meanwhile, 
Oklahoma has already modified the state’s protocol by increasing the 
dose of midazolam that will be administered to inmates in future 
executions.16 
More recently, on July 23, 2014, the execution of Joseph Wood in 
Arizona lasted for nearly two hours, with the inmate struggling to 
breathe and gasping over 600 times, according to a local reporter 
witnessing the execution.17 As the reporter described it: “The movement 
was like a piston: The mouth opened, the chest rose, the stomach 
convulsed . . . .”18 Arizona used two drugs, hydromorphone and 
midazolam,19 which had previously been used in a botched execution in 
Ohio in January 2014.20 The execution log reveals that Wood was 
injected with the drugs fifteen times in 114 minutes.21 In the middle of 
clayton-lockett/; see also Katie Zezima, Okla. Attorney General Seeks Execution Delay Following 
Botched Lethal Injection, WASH. POST (May 8, 2014), http://www.washingtonpost.com/blogs/post-
politics/wp/2014/05/08/okla-attorney-general-seeks-execution-delay-following-botched-lethal-
injection. 
15. Complaint at 1–2, Lockett v. Fallin, No. 5:2014-cv-01119-HE (W.D. Okla. Oct. 13, 2014) 
(arguing that “[d]espite innumerable treaties, protocols and accepted norms of human decency 
prohibiting human experimentation on unwilling subjects, while cast in the unwitting role of human 
lab rat for the Defendants, Clayton Lockett was administered an untested mixture of drugs that had 
not previously been used for executions in the United States”). The ACLU and news organizations 
have also filed suit since reporters were not allowed to observe the entire Lockett execution. See 
Lawsuit Seeks Uncensored Access to Executions, Citing First Amendment Press Freedom, ACLU 
(Aug. 25, 2014), https://www.aclu.org/free-speech/aclu-and-news-organizations-sue-over-closed-
blinds-during-botched-lockett-execution.  
16. Erik Eckholm, Oklahoma Executes First Inmate Since Slipshod Injection in April, N.Y. TIMES 
(Jan. 15, 2015), http://www.nytimes.com/2015/01/16/us/oklahoma-execution-charles-warner-lethal-
injection.html?_r=2; see also Josh Sanburn, Ohio Ups Lethal-Injection Dosages After Controversial 
Execution, TIME (Apr. 28, 2014), http://time.com/80092/ohio-lethal-injection-dosages-execution. 
17. Fernanda Santos & John Schwartz, A Prolonged Execution in Arizona Leads to a Temporary 
Halt, N.Y. TIMES (July 24, 2014), http://www.nytimes.com/2014/07/25/us/a-prolonged-execution-
in-arizona-leads-to-a-temporary-halt.html?_r=0. 
18. Mark Kiefer, Reporter Describes Arizona Execution, ARIZ. REPUBLIC (July 26, 2014), 
http://www.azcentral.com/story/news/arizona/politics/2014/07/24/arizona-execution-joseph-wood-
eyewitness/13083637/. 
19. Santos & Schwartz, supra note 17. 
20. Ohio to Increase Lethal Injection Drug Dosages After Execution Leads to Lawsuit, THE 
GUARDIAN (Apr. 28, 2014, 5:45 PM), http://www.theguardian.com/world/2014/apr/28/ohio-
increase-lethal-drug-dosages. 
21. Mark Berman, The Prolonged Arizona Execution Used 15 Doses of Lethal Injection Drugs, 
WASH. POST (Aug. 4, 2014), http://www.washingtonpost.com/news/post-nation/wp/2014/08/04/the-
prolonged-arizona-execution-used-15-doses-of-lethal-injection-drugs/. The execution log has been 
made available here: http://www.scribd.com/doc/235854026/Joseph-Wood-execution-log. 
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the execution, attorneys for Mr. Wood filed an emergency appeal to a 
federal district court to stop it.22 The transcript of this appeal reveals a 
great deal of confusion, with the state attorney general initially stating 
that Wood was brain dead, even though he was still breathing 
independently—a medical impossibility.23 The court was not convinced 
that stopping the execution would eliminate pain or suffering given that 
the inmate’s heart rate was slowing, and was also concerned that 
stopping the execution might do more harm than good.24 Mr. Wood was 
declared dead before the hearing concluded.25 The governor of Arizona, 
Jan Brewer, has announced that an investigation will be conducted into 
Wood’s execution, while expressing that eyewitness and media reports 
indicated that he did not suffer.26 
These examples are illustrative of a larger problem facing executions 
by lethal injection—the predominant method of execution used in the 
United States.27 A recent study has estimated that seven percent of all 
lethal injection executions have involved serious errors, which is a 
higher rate of failure than any other method of execution.28 
Commentators have begun to argue that when executions by lethal 
injection try out unproven drugs and novel procedures for use on non-
consenting inmates, lethal injection resembles “a nationwide, 
government-sponsored clinical trial”29 that raises ethical and regulatory 
concerns and violates international legal norms.30 Following the Lockett 
execution, a group of inmates in Oklahoma filed a lawsuit arguing that 
22. Kiefer, supra note 18. 
23. Transcript of Telephonic Motion for Emergency Stay of Execution at 7–8, Wood v. Ryan, 
No. CV 14-1447-PHX-NVW (D. Ariz. July 23, 2014), available at http://www.scribd.com/doc/ 
234993495/Transcript-related-to-Joseph-Wood-execution. 
24. Id. at 15–18. 
25. Id. at 16. 
26. Jacob Gershman, Arizona Inmate Dies 2 Hours After Start of Execution, WALL ST. J. (July 24, 
2014, 7:11 AM), http://www.wsj.com/articles/arizona-inmate-joseph-rudolph-wood-dies-2-hours-
after-start-of-execution-1406159321.   
27. Deborah W. Denno, Lethal Injection Chaos Post-Baze, 102 GEO. L.J. 1331, 1342–43 (2014). 
28. AUSTIN SARAT ET AL., GRUESOME SPECTACLES: BOTCHED EXECUTIONS AND AMERICA’S 
DEATH PENALTY 120, app. A at 177 (2014). 
29. Jeff Stryker, Lethal Injections: Medicine and Research, HASTINGS CTR. REP., Jan.–Feb. 2008, 
at 53.  
30. Johnny Holschuh, Experimenting with Death: Baze v. Rees, the Execution of Dennis 
McGuire, and the Constitutionality of Experimenting with Lethal Injection Drugs, U. CIN. L. REV. 
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lethal injection involves unconstitutional experimentation on prisoners.31 
Although it is increasingly common to refer to lethal injection 
executions as experimental,32 this Article is the first to conduct a 
rigorous analysis of whether and to what extent executions by lethal 
injection involve the conduct of research and therefore should be 
analyzed under the ethical and regulatory framework that governs 
biomedical research. 
In this Article, I argue that it is theoretically helpful to understand 
recent changes to execution protocols as a kind of biomedical research. 
By trying novel drugs, drug combinations, and dosages to see if they 
will work, states are conducting a type of biomedical research—namely, 
research that is poorly designed and not based in evidence. Although 
each execution involves changes that affect only one inmate, states make 
changes after botched executions and try to improve their protocols to 
use on other inmates on death row. There are several different 
regulations governing research, some promulgated by federal agencies 
(like the Department of Health and Human Services (DHHS), the 
Bureau of Prisons, and the Food and Drug Administration (FDA)), and 
also state statutes on research on prisoners. These regulations define 
research very differently. Not all regulations will cover this type of 
research, but state statutes and FDA regulations have broad enough 
31. Katie Fretl, Oklahoma Inmates File Lawsuit over “Unconstitutional” Executions, THE 
GUARDIAN (June 25, 2014, 3:39 PM), http://www.theguardian.com/world/2014/jun/25/oklahoma-
death-row-inmates-file-lawsuit-unconstitutional-executions (“The plaintiffs are not challenging their 
convictions or sentences of death in this action, . . . . They are challenging only the way in which 
their sentences of death will be carried out by the defendants.” (internal quotations omitted)). 
32. See, e.g., In re Ohio Execution Protocol Litig., 994 F. Supp. 2d 906, 913 (S.D. Ohio 2014) 
(“There is absolutely no question that Ohio’s current protocol presents an experiment in lethal 
injection processes. The science involved, the new mix of drugs employed at doses based on theory 
but understandably lacking actual application in studies, and the unpredictable nature of human 
response make today’s inquiry at best a contest of probabilities.”); JOHNS HOPKINS CLINIC FOR PUB. 
HEALTH LAW & POLICY, STATE DEPARTMENTS OF CORRECTIONS ARE VIOLATING FDA’S 
INVESTIGATIONAL NEW DRUG REGULATIONS BY EXPERIMENTING WITH LETHAL INJECTION DRUGS 
(2014), available at http://www.jhsph.edu/research/centers-and-institutes/center-for-law-and-the-
publics-health/Lethal%20Injection%20Policy%20Paper%20Final.pdf; Leonard G. Koniaris et al., 
Ethical Implications of Modifying Lethal Injection Protocols, 5 PLOS MED. 845 (2008); Seema K. 
Shah, How Lethal Injection Reform Constitutes Impermissible Research on Prisoners, 45 AM. 
CRIM. L. REV. 1101 (2008); Della Hasselle, Lawyers Argue that Next Week’s Execution Could 
Amount to “Human Experimentation,” THE LENS (Jan. 28, 2014), http://thelensnola.org/2014/ 
01/28/lawyers-argue-that-next-weeks-execution-could-amount-to-human-experimentation/; Sarah 
Lazare, “Experimenting” on a Death Row Inmate: Florida to Execute Man by Untested Drug, 
COMMON DREAMS (Oct. 15, 2014), http://www.commondreams.org/news/2013/10/15/ 
experimenting-death-row-inmate-florida-execute-man-untested-drug; Ruth Macklin, Is Execution by 
Lethal Injection Medical Research?, DOCTOR’S TABLET BLOG (May 6, 2014), 
http://blogs.einstein.yu.edu/is-execution-by-lethal-injection-medical-research/.  
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definitions to apply to experimental executions. However, states are 
conducting experimental executions without considering the ethical and 
regulatory framework that has been developed for biomedical research 
and the resulting legal safeguards. In particular, research with captive 
and vulnerable populations requires adherence to the ethical principles 
of respect for autonomy, non-maleficence, and justice. Viewing lethal 
injection executions through this lens can help ensure that states have a 
solid scientific basis and are neither excessively risky nor disrespectful 
of inmates on death row. 
Additionally, the ethical and regulatory framework governing 
biomedical research can complement an Eighth Amendment analysis. A 
research ethics framework offers a way to adjudicate amongst competing 
risk standards for determining how to apply the prohibition on cruel and 
unusual punishment to risks posed by executions by lethal injection. The 
most recent lethal injection case to be heard by the Supreme Court, Baze 
v. Rees,33 did not provide clear guidance on the appropriate standard for 
weighing risks.34 The Supreme Court has now granted certiorari to 
review Oklahoma’s execution protocol in the case of Glossip v. Gross,35 
and is likely to address the changes in execution drugs being used since 
its ruling in Baze.36 Importantly, the plurality opinion in Baze indicated 
that a lethal injection protocol would violate the Eighth Amendment if it 
involves a “substantial risk of serious harm” or an “objectively 
intolerable risk of harm,” and there are alternative execution methods 
that effectively address this risk.37 When faced with examples of 
problematic executions, the Court opined that “an isolated mishap,” or 
an “accident, with no suggestion of malevolence” would not be enough 
to sustain a challenge based on the Eighth Amendment.38 Yet, states are 
increasingly engaged in experimentation that disregards many potential 
risks and the considerable uncertainty as to whether procedures will 
work as planned. Given the growing number of examples of executions 
gone wrong, it is difficult to believe that these failures are merely a 
series of accidents. Rather, the problem is systemic and foreseeable. 
Poorly regulated and haphazard experimentation on inmates predictably 
leads to bad outcomes. 
33. 553 U.S. 35 (2008). 
34. Id. at 52.  
35. Warner v. Gross, No. CIV–14–0665–F, 2014 WL 7671680 (W.D. Okla. Dec. 22, 2014), aff’d, 
776 F.3d 721 (10th Cir. 2015), cert. granted, No. 14-7955, 2015 WL 302647 (U.S. Jan. 23, 2015). 
36. Id. 
37. Baze, 553 U.S. at 50, 52. 
38. Id. at 50. 
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To put this argument in context, it is important to understand that the 
examples of botched executions described above and in the media are 
attributable to the recent, rapid pace of change in executions by lethal 
injection across the country. These developments give new reason to be 
concerned about the uncertain and troubling risks of excruciating pain 
and suffering prior to death. The lethal injection approach traditionally 
used by states was a three-drug protocol, which led to a risk that any 
pain and suffering experienced by the inmate would be masked by the 
use of a paralytic agent.39 Now, states are using new drugs, in new 
combinations and doses, and making such quick changes to their 
protocols that it is increasingly difficult to predict what the outcome of a 
given execution might be.40 Moreover, many inmates were or could be 
subjects of this experimentation: thirty-nine inmates were executed in 
2013, thirty-five were executed in 2014, and over 3,000 inmates remain 
on death row.41 
For the sake of clarity, a caveat may be in order. This Article is not 
advocating for or against the death penalty or executions by lethal 
injection. Rather, the goal of this Article is to ensure that—given that 
execution by lethal injection persists in many states—it is properly 
regulated and borrows from well-thought-out standards developed in 
bio-medical research that address the concerns that arise when the 
interests of experimenters, their subjects, and the rest of society diverge, 
and the subjects of these experiments face uncertain risks of bodily 
harm. 
This argument is developed in four parts. In Part I of the Article, I 
describe the history of research ethics and regulation, with extra 
attention to research conducted on prisoners. Understanding the troubled 
history of research on prisoners helps make sense of the existing ethical 
and regulatory protections governing research on prisoners. In Part II, I 
explain how current lethal injection protocols came into being. I then 
argue in Part III that the best way to understand lethal injection 
experimentation is through the lens of evidence-based medicine. I 
contend that executions by lethal injection involve biomedical research 
39. Denno, supra note 27, at 1333–34. 
40. Id. at 1358 chart 3. 
41. Death Row Inmates by State as of October 1, 2014, DEATH PENALTY INFO. CTR., 
http://www.deathpenaltyinfo.org/death-row-inmates-state-and-size-death-row-year (last visited Jan. 
23, 2014); Execution List 2013, DEATH PENALTY INFO. CTR., 
http://www.deathpenaltyinfo.org/execution-list-2013 (last visited Feb. 9, 2015). Thirty-five people 
were executed in 2014. Execution List 2014, DEATH PENALTY INFO. CTR., 
http://www.deathpenaltyinfo.org/execution-list-2014 (last visited Feb. 9, 2015). 
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that is poorly designed and not based in evidence. Part IV argues that 
states should therefore either rely on existing evidence or conduct more 
systematic research, and identifies the regulations that should be applied 
to lethal injection. In this section, I also take note of the gaps in the 
regulation of poorly conducted research, and determine which 
regulations are drafted broadly enough to apply to experimental 
executions. I conclude by briefly addressing alternative approaches to 
executions and the challenges they involve, and considering the 
implications of this analysis for future scholarly work on both execution 
by lethal injection and biomedical research regulation and ethics. 
I. A BRIEF HISTORY OF RESEARCH ON PRISONERS 
This section first provides historical background for the development 
of principles and regulations that govern the conduct of biomedical 
research in the United States, with a particular focus on research on 
prisoners. Next, I address a potential objection to the line of argument 
contained in this Article: Why is it appropriate to apply the principles 
and protections governing biomedical research with human subjects to 
the context of capital punishment? I argue that the contexts of research 
and capital punishment are not as different as they might initially seem 
to be, and that there are important lessons learned from the history of 
research on prisoners that should not be forgotten. The mere fact that an 
inmate is sentenced to death should not suspend the standard protections 
to which all of us are entitled. 
A. History of Research Ethics and Regulation 
The ethics and regulation of clinical research have famously been 
described as “born in scandal and reared in protectionism.”42 This quote 
is a particularly apt characterization of the history of research on 
prisoners. In his book, Acres of Skin, Allen Hornblum chronicles several 
studies in which prisoners were used as research subjects without 
concern for their welfare.43 Many of these early experiments 
demonstrated a willingness to expose inmates to very high risks of injury 
or death, and also had an insufficient scientific basis for pursuing such 
an investigation in the first place.44 In fact, in the Nuremberg trials, Nazi 
42. Carol Levine, Has AIDS Changed the Ethics of Human Subjects Research?, 16 L. MED. & 
HEALTH CARE 167, 167 (1988). 
43. See generally ALLEN M. HORNBLUM, ACRES OF SKIN: HUMAN EXPERIMENTS AT 
HOLMESBURG PRISON (1998). 
44. Id. at xviii–xx. 
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physicians who had conducted unconscionable experimentation on 
victims of the Holocaust tried to defend their actions by arguing that 
U.S. physicians had long conducted similarly disturbing experiments on 
prisoners.45 In describing what motivated these uses of prisoners in 
research, some scholars argue that “a social consensus that certain 
subgroups are unequal can seem to justify experimentation that 
otherwise might not occur.”46 
One example cited at Nuremberg was a poorly run cholera trial 
conducted by an American physician in the Philippines in 1906.47 At the 
time, the Philippines was an American territory, and Dr. Richard Strong 
was a laboratory director at the Philippine Bureau of Science. Dr. Strong 
conducted potentially fatal experiments on death row inmates in Manila 
without their consent.48 Although a U.S. government report concluded 
that the deaths occurred because these inmates were mistakenly injected 
with plague serum instead of cholera serum, others believed that the 
inmates were deliberately injected with plague to try to induce an 
immune response.49 Dr. Strong subsequently conducted experiments on 
prisoners by withholding adequate nutrition and thereby causing them to 
develop beriberi, a serious disease that could cause paralysis and heart 
failure.50 These experiments also resulted in several deaths.51 Similar 
research on nutrition occurred within the United States. Around this 
same time, the Louisiana Board of Health put black prisoners on a strict 
diet of molasses for five weeks to learn whether sulfuric acid (used in 
making molasses) was harmful.52 
Experimentation on prisoners became much more prevalent during 
World War II, when physicians struggled to find treatments for the 
diseases that were afflicting American soldiers.53 The Terre Haute 
Experiments, which were conducted between 1943 and 1944,54 were 
designed to develop a technique that would consistently infect prisoners 
45. Id. at xvi. 
46. Valerie H. Bonham & Jonathan D. Moreno, Research with Captive Populations: Prisoners, 
Students, and Soldiers, in THE OXFORD TEXTBOOK OF CLINICAL RESEARCH ETHICS 461, 463 
(Ezekiel J. Emanuel et al. eds., 2008). 





52. Id. at 76–77. 
53. Id. at 80–83. 
54. PRESIDENTIAL COMM’N FOR THE STUDY OF BIOETHICAL ISSUES, “ETHICALLY IMPOSSIBLE” 
STD RESEARCH IN GUATEMALA FROM 1946 TO 1948, at 13 (2013). 
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with gonorrhea by applying bacteria to the prisoners’ genitals.55 These 
experiments were the precursor to even more egregious experiments 
later conducted in Guatemala, for which the U.S. government has 
formally apologized.56 
Some experiments even involved prisoners on death row. The New 
York Times wrote about a case where a prisoner was pardoned from a 
death sentence as a result of participation in a risky medical 
experiment.57 One physician wrote a letter to the New York Times 
criticizing the lack of a scientific basis for the study and the risks 
involved.58 Human experimentation with prisoners was commonplace by 
the 1950s and 60s.59 By the 1970s, approximately eighty-five percent of 
all phase I trials (or studies conducted with the primary objective of 
learning about the safety of the experimental intervention, and not to 
benefit the subjects of the research) were conducted on prisoners.60 
In 1962, one of the first efforts to examine the ethics of research on 
prisoners took place at a conference held at Boston University.61 The 
conference attendees, among whom were both researchers and prison 
officials, felt that research on prisoners was not likely to be of concern 
for the general public, stating: “When the public hears that inmates are 
[participating in a seemingly very hazardous study], they rationalize 
‘Well, I wouldn’t do it, but it’s all right with prisoners.’”62 Many also 
thought that the public would be more willing than researchers to have 
prisoners be exposed to high risks.63 
Given this history, it is surprising to learn that the principles 
governing ethically responsible research were established prior to these 
scandals, in the early twentieth century.64 The physician William Osler 
55. Id. at 21 (the presumption was that prisoners would volunteer in order to help the war effort). 
56. Donald G. McNeil, Jr., Syphilis Experiment Is Revealed, Prompting U.S. Apology to 
Guatemala, N.Y. TIMES, Oct. 1, 2010, at A1. 
57. Id. at 87–88. 
58. Id. at 89. 
59. HORNBLUM, supra note 43, at xviii.  
60. Proposed Rules, 42 Fed. Reg. 3085 (proposed Jan. 14, 1977) (to be codified at 45 C.F.R. pt. 
46); NAT’L COMM’N FOR THE PROT. OF HUMAN SUBJECTS OF BIOMEDICAL & BEHAVIORAL 
RESEARCH, REPORTS & RECOMMENDATIONS: RESEARCH INVOLVING PRISONERS 47 (1976) 
[hereinafter RESEARCH INVOLVING PRISONERS].  
61. Bonham & Moreno, supra note 46, at 463. 
62. Id. at 463. 
63. See id.  
64. See, e.g., SUSAN E. LEDERER, SUBJECTED TO SCIENCE: HUMAN EXPERIMENTATION IN 
AMERICA BEFORE THE SECOND WORLD WAR 22 (1995) (citing prominent physician William Osler 
for his criticism of a study that failed to obtain informed consent in 1898); Paul J. Weindling, The 
Nazi Medical Experiments, in THE OXFORD TEXTBOOK OF CLINICAL RESEARCH ETHICS 18, 19 
 
                                                     
 
08 - Shah - final.docx (Do Not Delete) 4/13/2015  11:51 AM 
158 WASHINGTON LAW REVIEW [Vol. 90:147 
argued in 1907 that interventions could be tested in humans only after 
animal testing had occurred, consent was obtained from the research 
subjects, and direct benefit to the individual subjects was likely.65 
Eventually, research on prisoners that violated these and other ethical 
principles led to controversy. Newspaper editorials questioned whether 
prisoners were coerced into research participation.66 Congressional 
hearings were held in 1973, in which concerns about “exploitation, 
secrecy, danger, and the impossibility of obtaining informed consent” 
were cited as reasons to prohibit research on prisoners.67 As a result of 
these hearings, a bill was introduced to establish the National 
Commission for the Protection of Human Subjects of Biomedical and 
Behavioral Research.68 
In the late 1970s, Congress gave the Commission the task to “identify 
the basic ethical principles that should underlie the conduct of 
biomedical and behavioral research involving human subjects and to 
develop guidelines to assure that such research is conducted in 
accordance with those principles.”69 The Commission authored the 
Belmont Report, one of the most influential documents in research ethics 
to date. In this report, the Commission addressed “the boundaries 
between biomedical and behavioral research and the accepted and 
routine practice of medicine.”70 The resulting discussion is particularly 
instructive here. 
The Commission recognized that it is important to distinguish 
between biomedical research and clinical practice, but that it can be 
challenging to draw this distinction given that “notable departures from 
standard practice are often called ‘experimental’ when the terms 
(Ezekiel J. Emanuel et al. eds., 2008) (citing the German Reich Circular on Human Experimentation 
from 1931, which required advance consent to research and limits on research with children). 
65. Arthur O. Anderson & James R. Swearengen, Scientific and Ethical Importance of Animal 
Models in Biodefense Research, in BIODEFENSE: RESEARCH METHODOLOGY AND ANIMAL MODELS 
25, 27 (James R. Swearengen ed., 2012) (citing William Osler, The Historical Development and 
Relative Value of Laboratory and Clinical Methods in Diagnosis. The Evolution of the Idea of 
Experiment in Medicine, in TRANSACTIONS OF THE CONGRESS OF AMERICAN PHYSICIANS AND 
SURGEONS 1–8 (1907)), available at http://artandersonmd.com/ 
2006.animal.models.biodefense.research.pdf). 
66. Id. at 3. 
67. RESEARCH INVOLVING PRISONERS, supra note 60, at 3.  
68. Id. at 3–4.  
69. NAT’L COMM’N FOR THE PROT. OF HUMAN SUBJECTS OF BIOMEDICAL & BEHAVIORAL 
RESEARCH, THE BELMONT REPORT: ETHICAL PRINCIPLES AND GUIDELINES FOR THE PROTECTION 
OF HUMAN SUBJECTS OF RESEARCH 1 (1979) [hereinafter THE BELMONT REPORT]. 
70. Id. 
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‘experimental’ and ‘research’ are not carefully defined.”71 The 
Commission argued that the distinction is largely based on the intent 
behind the activity. Essentially, medical practice is about helping 
individual patients, whereas research is about learning from individuals 
to develop knowledge that can be applied to other, future patients.72 Any 
departure from standard practice does not necessarily constitute 
research, however; nor does “the fact that a procedure is ‘experimental,’ 
in the sense of new, untested or different” turn it into research.73 Yet, the 
Commission cautioned, experimental procedures should “be made the 
object of formal research at an early stage in order to determine whether 
they are safe and effective.”74 
After discussing the boundary between research and practice, the 
Commission turned its attention to the general principles that should 
govern the conduct of research. It determined that three core ethical 
principles should apply to research: respect for persons, beneficence, and 
justice.75 Respect for persons requires recognizing that individuals 
should be treated as autonomous agents, and individuals who are not 
able to make their own decisions should be protected from risk. 
Respecting autonomous individuals serves at least two functions. The 
value of treating individuals as autonomous agents is not just to show 
them respect by letting them do as they choose (within certain 
constraints, of course), but also because individuals are often best-
positioned to make decisions that protect their own interests. The 
Commission specifically applied this principle to the conduct of research 
involving prisoners as follows: 
In most cases of research involving human subjects, respect for 
persons demands that subjects enter into the research voluntarily 
and with adequate information. In some situations, however, 
application of the principle is not obvious. The involvement of 
prisoners as subjects of research provides an instructive 
example. On the one hand, it would seem that the principle of 
71. Id. at 3. 
72. Id. More specifically, the National Commission contended that medical practice refers to 
“interventions that are designed solely to enhance the well-being of an individual patient or client 
and that have a reasonable expectation of success. The purpose . . . is to provide diagnosis, 
preventative treatment, or therapy to particular individuals.” Id. at 3–4. By contrast, research is an 
“activity designed to test an hypothesis, permit conclusions to be drawn, and thereby to develop or 
contribute to generalizable knowledge . . . . Research is usually described in a formal protocol that 
sets forth an objective and a set of procedures designed to reach that objective.” Id. at 4. 
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respect for persons requires that prisoners not be deprived of the 
opportunity to volunteer for research. On the other hand, under 
prison conditions they may be subtly coerced or unduly 
influenced to engage in research activities for which they would 
not otherwise volunteer. Respect for persons would then dictate 
that prisoners be protected. Whether to allow prisoners to 
“volunteer” or to “protect” them presents a dilemma. Respecting 
persons, in most hard cases, is often a matter of balancing 
competing claims urged by the principle of respect itself.76 
The Commission determined that, in research, the principle of respect 
for persons requires asking potential research subjects for their informed 
and voluntary consent to participate in the research, provided that they 
are capable of making their own decisions. They also specified that this 
requires informing potential research subjects about “the research 
procedure, their purposes, risks and anticipated benefits, alternative 
procedures (where therapy is involved), and a statement offering the 
subject the opportunity to ask questions and to withdraw at any time 
from the research.”77 
The second principle the Commission thought should be applied to 
research with human subjects is the principle of beneficence. Although it 
described this principle as requiring that researchers do no harm, 
maximize possible benefits, and minimize potential harms,78 it is not 
straightforward to apply the principle of beneficence to research. 
Because research involves testing interventions with uncertain risks and 
benefits, and research procedures are sometimes needed to understand 
how these interventions are working in the body, it is difficult to 
conceive of research that would not do any harm. Moreover, the 
requirement to maximize benefits could be overly demanding and come 
into conflict with the primary duty that researchers have to develop 
generalizable knowledge. Therefore, scholars now understand the 
obligation of beneficence to require that harms are minimized in 
research, and that unnecessary harms are not imposed on research 
subjects.79 This is also consistent with the way the Commission applied 
the principle of beneficence in the Belmont Report—it notes that 
beneficence requires the systematic assessment of risks and benefits, and 
ensuring that “risks should be reduced to those necessary to attain the 
76. Id. at 5. 
77. Id. at 7. 
78. Id. at 5. 
79. Steven Joffe & Franklin G. Miller, Bench to Bedside: Mapping the Moral Terrain of Clinical 
Research, HASTINGS CTR. REP., Mar.–Apr. 2008, at 30, 36. 
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research objective.”80 
The final principle the Commission argued should apply to research is 
justice. In research, justice requires the fair and equal distribution of the 
burdens and benefits of research. In particular, it explained that “the 
principle of justice gives rise to moral requirements that there be fair 
procedures and outcomes in the selection of research subjects.”81 It was 
particularly concerned that only “undesirable” persons might be selected 
for risky research.82 
In a subsequent report, the Commission was also charged with 
specifically addressing the participation of prisoners in biomedical and 
behavioral research.83 The Commission noted that, in general, prisoners 
did not participate in biomedical research outside the United States, and 
attributed this to international concern about experiments conducted by 
the Nazis on holocaust victims.84 The Commission raised two important 
ethical concerns about prisoner participation in research: exploitation 
and autonomy. The Commission specifically was concerned that (1) 
prisoners were being exploited by being exposed to risky research, and 
(2) prisoners may not be able to give voluntary informed consent to 
research participation because they live in a coercive environment.85 The 
Commission made a strong statement about the importance of protecting 
prisoners from exploitation: 
It has become evident to the Commission that, although 
prisoners who participate in research affirm that they do so 
freely, the conditions of social and economic deprivation in 
which they live compromise their freedom. The Commission 
believes, therefore, that the appropriate expression of respect 
consists in protection from exploitation. Hence it calls for 
certain safeguards intended to reduce the elements of constraint 
under which prisoners give consent and suggests that certain 
kinds of research would not be permitted where such safeguards 
cannot be assured.86 
The Commission’s report led to strict regulations governing research 
on prisoners. Various federal agencies have promulgated regulations 
greatly influenced by the Commission’s report. For example, 
80. THE BELMONT REPORT, supra note 69, at 10.  
81. Id. at 11. 
82. Id. 
83. See RESEARCH INVOLVING PRISONERS, supra note 60, at vii–ix.  
84. Id. at 2–3. 
85. Id. at 5. 
86. Id. at 6–7. 
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Department of Health and Human Services (DHHS) regulations provide 
that research on prisoners should not take place unless the research is 
likely to have some benefit for prisoners as a group or for individual 
prisoners enrolled in the research.87 There are also regulations 
promulgated by the Federal Bureau of Prisons that stem from the 
Commission’s work; these regulations govern research involving 
prisoners that is conducted within the Federal Bureau of Prisons. These 
regulations are slightly different from the DHHS regulations.88 Finally, 
the Food and Drug Administration (FDA) attempted to enact a set of 
prisoner regulations similar to those adopted by the DHHS in 1978.89 
However, presumably out of concern that they would not have access to 
potentially beneficial research, prisoners in the Michigan State 
Penitentiary alleged that these proposed regulations violated the Equal 
Protection and Due Process Clauses of the Fifth Amendment.90 The 
existing FDA regulations that cover human subjects research in general 
do, however, have at least one protection that would apply to research 
with prisoners. Current FDA regulations require that Institutional 
Review Boards (IRBs), which regularly review research involving a 
particular vulnerable group (such as prisoners), consider including 
someone on the board who has knowledge and expertise in working with 
members of the group.91 
Many states have also passed laws of varying degrees of 
restrictiveness that limit or even prohibit the conduct of research on 
prisoners within state departments of corrections.92 This protectionist 
response was viewed by many as an overcorrection, which led to 
prisoners being denied the benefits associated with some types of 
research and insufficient investigation of the kinds of illnesses that 
87. See 45 C.F.R. § 46 subpart C (2014). The exceptions provided in this subpart are discussed at 
greater length in Part III.C, infra. 
88. See 28 C.F.R. § 512 (2014). Note that unlike the DHHS regulations, which only apply to 
federally funded research, the Bureau of Prisons regulations appear to apply to any research 
conducted within the Bureau. Id. § 512.10. Furthermore, although some research conducted by 
employees of the Bureau is exempt from some regulations, no research is exempt from part 512, 
which is the relevant part for my analysis. Id. 
89. 45 Fed. Reg. 19,417, 19,418 (May 5, 1978) (to be codified at 21 C.F.R. pt. 50 Subpart C) 
(referring to subpart C of the DHHS regulations, but going beyond these regulations by including 
statements such as: “no prisoner may serve as a placebo control”). 
90. See Sharona Hoffman, Beneficial and Unusual Punishment: An Argument in Support of 
Prisoner Participation in Clinical Trials, 33 IND. L. REV. 475, 491–92 (2000). 
91. 21 C.F.R. § 56.107(a) (2014); id. § 56.111. Note, however, that the FDA revoked these 
regulations in 1997 for being “obsolete or no longer relevant to public health goals.” 62 Fed. Reg. 
39,439 (July 23, 1997). 
92. Shah, supra note 32, at 1146 app. 1. 
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disproportionately affect prisoners. In fact, an Institute of Medicine 
committee issued a report in 2006, in which it acknowledged “that 
access to research may be critical to improve the health of prisoners and 
the conditions in which they live.”93 The report argued that more 
research calculated to benefit individual inmates and prisoners as a 
group should be permitted.94 Despite this regulatory response to abuses 
and scandals of the past, public distrust of biomedical research persists,95 
particularly among African-Americans.96 This distrust may stem from 
historical scandals in research involving African-Americans, and may 
also incorporate a more general lack of trust based on the legacy of 
discrimination against African-Americans in the U.S.97 
In sum, the history of research involving prisoners in the United 
States led to the recognition that the principles of respecting autonomy, 
beneficence, justice, and avoiding exploitation should guide the conduct 
of research with human subjects. This history also led to the 
development of strict research regulations that, as I will argue below, 
apply to some of the current experimentation on lethal injection. First, I 
will head off an important potential objection to this line of inquiry—
should ethical principles and legal protections developed for research 
subjects be applied to the domain of capital punishment? 
B. Should Research Protections Apply to Capital Punishment? 
Biomedical research involves risks of bodily harm and a divergence 
93. COMM’N ON ETHICAL CONSIDERATION FOR REVISIONS TO DHHS REGULATIONS FOR PROT. 
OF PRISONERS INVOLVED IN RESEARCH, ETHICAL CONSIDERATIONS FOR RESEARCH INVOLVING 
PRISONERS 4 (Lawrence O. Gostin et al. eds., 2007) [hereinafter ETHICAL CONSIDERATIONS]. The 
Institute of Medicine is an arm of the National Academy of Sciences that regularly convenes 
committees to issue influential reports, often at the behest of Congress or federal agencies. See 
About the IOM, INST. OF MED., http://iom.edu/About-IOM.aspx (last visited Nov. 4, 2013).  
94. ETHICAL CONSIDERATIONS, supra note 93, at 4. 
95. Raegan W. Durant et al., Different Types of Distrust in Clinical Research Among Whites and 
African Americans, 103 J. NAT’L. MED. ASS’N. 123, 123 (2011). 
96. See, e.g., Joel B. Braunstein et al., Race, Medical Research Distrust, Perceived Harm, and 
Willingness to Participate in Cardiovascular Prevention Trials, 87 MED. 1, 5 (2008); Giselle 
Corbie-Smith et al., Distrust, Race, and Research, 162 ARCHIVES OF INTERNAL MED. 2458, 2459 
(2002); Vickie L. Shavers, Charles F. Lynch, & Leon F. Burmeister, Knowledge of the Tuskegee 
Study and its Impact on the Willingness to Participate in Medical Research Studies, 92 J. NAT’L 
MED. ASS’N. 563, 567 (2000). I have noted elsewhere that lethal injection research has the potential 
to harm biomedical research, given that distrust of research is particularly high among African-
Americans, and that African-Americans are overrepresented on death row. Shah, supra note 32, at 
1146 n.232. 
97. Jill A. Fisher & Corey A. Kalbaugh, Challenging Assumptions About U.S. Minority 
Participation in U.S. Clinical Research, 101 AM. J. PUB. HEALTH 2217, 2218–19 (2011). 
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of interests between those conducting research and those subjected to it. 
It is particularly vulnerable to exploitation and abuse. Research is an 
activity that involves trying interventions that may or may not work to 
produce scientific knowledge that can benefit others in society, and may 
pose risks of bodily harm for the individual subjects of the research. The 
interests of the researcher and the sponsors of the research are to find out 
something that was not previously known, and to receive benefits from 
the production of that knowledge. These benefits may include prestige, 
status, career advancement, satisfaction of curiosity, and money. By 
contrast, research subjects may benefit from the research intervention, 
but may also face significant risk. They are also unlikely to benefit from 
the production of the knowledge in a significant way. Safeguards for 
research have therefore been developed that help protect research 
subjects and ensure that valuable research can proceed and new 
knowledge can be generated. 
The current approaches to lethal injection executions involve 
exposing inmates to new and uncertain risks of bodily harm from 
untested drugs and drug combinations. The interests of prison officials 
are to find methods of lethal injection that are effective, appear to have a 
low risk of causing significant pain and suffering, and are based on using 
drugs they can access and procedures they can implement. There is great 
potential for abuse and exploitation of prisoners because prison officials’ 
interests differ so dramatically from those of inmates. There is 
considerable uncertainty about whether some of these drugs will cause 
death without also causing excessive and torturous pain. Additionally, 
executions are justified on the basis that they further societal goals of 
deterrence and retribution. The potential for abuse suggests that the 
principles and protections developed for biomedical research could be 
very helpful in regulating executions by lethal injection. 
Some might still question whether a research ethics framework is the 
right approach to address worries about execution methods for several 
reasons. First, perhaps executions should not be thought of as “medical” 
in any respect. Second, the historical examples of research on prisoners 
may differ in important respects from modern day executions by lethal 
injection. Third, one might argue that capital punishment should be 
judged on the basis of considerations specific to the criminal justice 
system (such as whether the approach to executions furthers its goals of 
deterrence and retribution), rather than the “subject protection” 
framework that applies to research. Perhaps the research ethics 
framework assumes a more robust conception of the interests and rights 
of subjects than should be applied to capital punishment. Finally, maybe 
death is different, and people who are already sentenced to death should 
 
08 - Shah - final.docx (Do Not Delete) 4/13/2015  11:51 AM 
2015] EXPERIMENTAL EXECUTION 165 
not receive the same protections that others would.98 
Some have argued that lethal injections should be considered outside 
of the practice of medicine altogether, and some states indicate in their 
statutory codes that lethal injection does not constitute the practice of 
medicine.99 However, for the purposes of this analysis, lethal injections 
do not have to be considered part of the practice of medicine. My 
argument is that lethal injection executions involve a type of biomedical 
research—something that is also outside the practice of medicine.100 
Additionally, Mark Heath argues that some components of lethal 
injection clearly use medical procedures for medical purposes. The 
administration of drugs that paralyze the inmate or that have the sole 
effect of causing death do not have clear medical purposes. But Heath 
argues that “[a]dministration of general anesthesia, including the 
induction, maintenance, and continued assessment of anesthetic depth, is 
done to prevent severe pain; it is a therapeutic procedure and a medical 
procedure.”101 The use of anesthesia is necessary for all current lethal 
injection protocols to avoid an unconstitutionally high risk of pain. This 
suggests that lethal injections in the United States have a medical 
component to them that cannot be removed. 
It is true that there are some important differences between the history 
of research on prisoners and current experimentation in lethal injection 
executions that may support differential treatment. First, execution 
research on inmates, unlike most research and most of the historical 
research on prisoners, enrolls individuals who are going to die shortly. 
This can be compared, however, to some examples of research on 
individuals who suffer from terminal illnesses102 or who will likely die 
98. Note that the Supreme Court has explained that the fact that “the penalty of death is different 
in kind from any other punishment imposed under our system of criminal justice” is a justification 
for heightened protections, and not a justification for less scrutiny. Gregg v. Georgia, 428 U.S. 153, 
188 (1976). 
99. See, e.g., Amended Order Granting Plaintiff’s Request for Declaratory Relief and Denying 
Defendant’s Motion to Dismiss, N.C. Dep’t of Corr. v. N.C. Med. Bd., No. 07-CV-003574 (N.C. 
Oct. 1, 2007); Complaint, N.C. Dep’t of Corr. v. N.C. Med. Bd., No. 07-CV-003574 (N.C. March 6, 
2007); Deborah W. Denno, The Lethal Injection Quandary: How Medicine Has Dismantled the 
Death Penalty, 76 FORDHAM L. REV. 49, 89 (2007) (explaining that eight states have statutes 
expressly indicating that lethal injection executions do not constitute the practice of medicine); 
William L. Lanier & Keith H. Burge, Physician Involvement in Capital Punishment: Simplifying a 
Complex Calculus, 82 MAYO CLINIC PROC. 1043, 1046 (2007). 
100. Paul Litton & Franklin G. Miller, What Physician-Investigators Owe Patients Who 
Participate in Research, 304 J. AM. MED. ASS’N 1491, 1491 (2010). 
101. Mark J. Heath, Revisiting Physician Involvement in Capital Punishment: Medical and 
Nonmedical Aspects of Lethal Injection, 83 MAYO CLINIC PROC. 115, 116 (2008). 
102. Erika Kleiderman et al., Recruiting Terminally Ill Patients into Non-Therapeutic Oncology 
Studies: Views of Health Professionals, 13 BMC MED. ETHICS 33, 34 (2012). 
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imminently.103 In these categories of research, although long-term risks 
may be discounted because subjects may not live long enough to 
experience these consequences, the ethical issues regarding the treatment 
of research subjects are still taken seriously.104 Similarly, there is no 
reason to disregard the risk of significant pain and suffering that an 
inmate will experience before being executed, simply because he will 
most likely be dead soon after experiencing them. Depending on why we 
think pain is a negative experience, however, there may be some reason 
to discount the pain experienced at the very end of life. There are at least 
two aspects of pain that make it bad—the actual experience of pain and 
the memory of it. Because inmates being executed will not live to 
remember their experience of pain, how bad it is for them to suffer at the 
end of life may need to be discounted from how we might ordinarily 
evaluate pain. On the other hand, studies conducted by psychologists 
asking subjects to evaluate the quality of different individuals’ lives 
suggest that negative experiences at the end of life color the evaluation 
of the life as a whole significantly.105 Somewhat counterintuitively, this 
research implies that there may be extra reason to think that severe pain 
at the end of life is bad. Thus, it is hard to establish conclusively whether 
the negative aspects of pain are diminished or increased if pain is 
experienced at the end of life. Perhaps the safest conclusion is that the 
fact that an inmate who is executed will not live to remember the pain 
may give some reason to discount the level of pain an inmate 
experiences, but does not eliminate other reasons to care about the 
experience of pain in an execution. 
Second, lethal injection experimentation may also differ from most of 
human subjects experimentation because it may be less motivated by 
scientific curiosity and the desire to improve human health. Such 
experimentation is presently motivated at least in part by political 
considerations and drug embargos that stem from ethical concerns about 
the death penalty.106 For example, a Danish drug maker and some 
American pharmaceutical companies have taken steps to prevent their 
drugs from being supplied to states for use in executions.107 Yet, at least 
103. Kate Murphy, Killing a Patient to Save His Life, N. Y. TIMES (June 9, 2014), 
http://www.nytimes.com/2014/06/10/health/a-chilling-medical-trial.html. 
104. Kleiderman et al., supra note 102, at 36–38. 
105. See DANIEL KAHNEMAN, THINKING FAST AND SLOW 387–88 (2011). 
106. Josh Sanburn, The Hidden Hand Squeezing Texas’ Supply of Execution Drugs, TIME (Aug. 
7, 2013), http://nation.time.com/2013/08/07/the-hidden-hand-squeezing-texas-supply-of-execution-
drugs/.  
107. Id.; see also Par Pharmaceutical Statement on Brevital® Sodium, PAR PHARMACEUTICALS 
(May 27, 2014), http://pr.parpharm.com/phoenix.zhtml?c=81806&p=irol-newsArticle&ID= 
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some biomedical research is conducted because of political 
considerations or moral concerns. Consider, for example, the increased 
research by the states and private companies spurred by President 
George W. Bush’s decision to severely restrict federal funding for 
research on the use of embryonic stem cell lines.108 
A third objection to considering certain aspects of lethal injection 
executions medical research is that execution and research serve 
different goals. In the history of research on prisoners and other 
vulnerable subjects, the aim was to test products that could benefit 
others. By contrast, some might argue that the goal of lethal injection 
experimentation is to successfully execute the particular inmate, or 
perhaps to make future executions of inmates more effective and less 
objectionable. If the goals of the two types of research are different, the 
history of research on prisoners may not help us to understand current 
experimentation on death row inmates. 
This objection, however, does not rely on an accurate view of the 
motivations of both stakeholders in research and those involved in 
conducting executions. Researchers and sponsors of research can have 
many different motivations. They may want to test a treatment on 
particular patients hoping to help those patients, and still have interests 
in whether the treatment is likely to be safe and effective for use in 
future patients.109 Researchers may also conduct research in order to 
satisfy their curiosity, build their reputation, or make money.110 
Similarly, although prison officials may want to ensure that a particular 
inmate is executed without incident, they may also be very interested in 
finding a method of execution that they can use without raising concern 
from activists, judges, and the general public. And those who support 
executions do so for at least one of a few different reasons. They may 
believe that executions have a deterrent effect and prevent future crime; 
they may think that punishment and retribution are morally appropriate 
for those who have committed crimes of a certain degree; or they may 
think that an execution gives comfort or justice to the victims of a crime 
and their families.111 This suggests that the purposes behind capital 
1935104 (“As a pharmaceutical company, Par’s mission is to help improve the quality of life. The 
state of Indiana’s proposed use is contrary to our mission.”). 
108. Eileen Burgin, Human Embryonic Stem Cell Research and Proposition 71: Reflections on 
California’s Response to Federal Policy, 29 POL. & LIFE SCI. 73 (2010); Constance Holden, States, 
Foundations Lead the Way After Bush Vetoes Stem Cell Bill, 313 SCI. 420 (2006). 
109. Joffe & Miller, supra note 79, at 33.  
110. David Korn, Conflicts of Interest in Biomedical Research, 284 J. AM. MED. ASS’N 2234, 
2234 (2000). 
111. Cass R. Sunstein & Adrian Vermeule, Is Capital Punishment Morally Required?: Acts, 
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punishment, like the purposes behind research, may include a desire to 
benefit society in some way. Thus, inmates on death row are not immune 
from the possibility of exploitation for the benefit of society. 
Some might object that there is no reason to apply extra protections 
for research on lethal injection because these prisoners are already 
sentenced to death. A more extreme view might be that any additional 
suffering is what death row inmates deserve, based on the crimes that led 
to a death sentence.112 Although the Constitution has been interpreted to 
permit the imposition of death sentences, it expressly forbids cruel and 
unusual punishment. Thus, unless the Constitution is amended to 
eliminate the cruel and unusual punishment clause of the Eighth 
Amendment or the death penalty is determined to be unconstitutional 
under evolving standards of decency,113 we must evaluate methods of 
execution to ensure that they are not cruel and unusual. As the U.S. 
Supreme Court explained in In re Kemmler,114 “[p]unishments are cruel 
when they involve torture or a lingering death; but the punishment of 
death is not cruel within the meaning of that word as used in the 
constitution. It implies there is something inhuman and barbarous—
something more than the mere extinguishment of life.”115 Austin Sarat 
further argues that an important purpose is served by ensuring that the 
death penalty is administered humanely: 
Even as capital punishment seeks to do justice and/or satisfy the 
public desire for vengeance, the state has countervailing 
concerns. It must distinguish execution from the acts to which it 
is a supposedly just response. The state must also find ways of 
killing in a manner that does not allow the condemned to 
become an object of pity, or to appropriate the status of the 
victim.116 
Sarat goes on to note that, “[l]aw imposes on sovereignty the 
requirement that no matter how heinous the crime or how reprehensible 
the criminal, we not do death as death has been done by those we 
Omissions, and Life-Life Tradeoffs, 58 STAN. L. REV. 703, 704–05 (2006). 
112. See Matt McCarthy, What’s the Best Way to Execute Someone?, SLATE (Mar. 27, 2014, 
11:44 PM), http://www.slate.com/articles/health_and_science/medical_examiner/2014/03/death_ 
penalty_drugs_lethal_injection_executions_are_so_bad_that_it_s_time.html. 
113. Trop v. Dulles, 356 U.S. 86, 100–01 (1958). 
114. 136 U.S. 436 (1890). 
115. Id. at 447. Although Kemmler has been cited in subsequent Supreme Court cases as confined 
to outlawing “barbarous” forms of punishment, the standards used by the Supreme Court today are 
meant to be broader than this and to reflect “evolving standards of decency.” See Gregg v. Georgia, 
428 U.S. 153, 173 (1976). 
116. SARAT ET AL., supra note 28, at 5. 
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punish . . . . We kill humanely, not out of concern for the condemned but 
rather to vividly establish a hierarchy between the law-abiding and the 
lawless.”117 This suggests that there is reason to ensure the death penalty 
is administered humanely whether or not one has any concern for the 
welfare of the inmates being executed. 
The research enterprise also depends on trust in the system, and to the 
extent that the public is beginning to view executions as poorly 
conducted research, public trust in research may be affected by lethal 
injection executions.118 Allowing death penalty research to proceed 
unchecked and immune from regulatory scrutiny sets a precedent that 
could erode confidence in research more generally, particularly as 
questions about the experimental nature of executions are asked more 
frequently.119 It is also true that many historical scandals arose out of 
research conducted on people who were considered disposable, or 
unworthy of moral consideration, by mainstream society.120 
Finally, and perhaps most importantly, it is not clear why the 
imposition of the death penalty should suspend all other legal 
protections. As the Supreme Court explained in a case about FDA 
review of lethal injection drugs, “The fact that the drugs involved in this 
case are ultimately to be used in imposing the death penalty must not 
lead this Court or other courts to import profound differences of opinion 
over the meaning of the Eighth Amendment to the United States 
Constitution into the domain of administrative law.”121 The same logic 
applies to the domain of research regulation. 
In sum, there are enough similarities and common principles shared 
between new death penalty protocols and more traditional biomedical 
research that it is appropriate to evaluate them in similar ways. As I will 
demonstrate below, insights from the domain of research ethics and 
regulation can help to ensure that executions by lethal injection are not 
excessively risky or disrespectful of inmates. 
II. HISTORICAL AND CURRENT DEVELOPMENTS IN 
EXECUTION BY LETHAL INJECTION 
Many articles have described the history of how the first lethal 
117. Id. at 28. 
118. See Alex J. London, A Non-Paternalistic Model of Research Ethics and Oversight: 
Assessing the Benefits of Prospective Review, 40 J.L. MED. & ETHICS 930, 930 (2012). 
119. See Kiefer, supra note 18. 
120. See Bonham & Moreno, supra note 46, at 461–63. 
121. Heckler v. Chaney, 470 U.S. 821, 838 (1985). 
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injection protocol was developed,122 so I will discuss the history only 
briefly and then turn to more recent changes to and problems with 
executions by lethal injection. 
A. Brief History of Execution by Lethal Injection 
The first time lethal injection was considered as a possible method of 
execution was in the late nineteenth century, when a New York state 
commission rejected it as an option based on the concern that the public 
would associate the practice of medicine with causing death.123 The 
U.K.’s Royal Commission on Capital Punishment conducted a study in 
the 1950s to evaluate the relative merits of execution by lethal injection 
versus execution by hanging, and identified several problems that led the 
members of the commission not to recommend lethal injection as a 
possible execution method.124 The Royal Commission was particularly 
concerned about problems associated with individuals with veins that 
were difficult to access and the need for someone on the execution team 
to have complex medical skills.125 The British Association of 
Anaesthetists explained to the Royal Commission that lethal injection 
was impractical because of concerns that: (1) it would be impossible to 
administer intravenous injections to people with “certain physical 
abnormalities,” (2) it is difficult to inject people against their will, and 
(3) medical skills and training would be needed, but members of the 
medical profession would not be willing to provide their assistance.126 
The Commission did believe, however, that lethal injection might be a 
more humane and painless method than other methods, and suggested 
that gradual adoption of lethal injection in a systematic manner, coupled 
with the state taking “all possible means to ensure that the act is 
122. Denno, supra note 99, at 64–65; see generally Shah, supra note 32.  
123. Denno, supra note 99, at 64. 
124. ROYAL COMM’N ON CAPITAL PUNISHMENT, 1949–1953, REPORT 261 (1953) (U.K.) (“Our 
own collective verdict must be a negative one: we cannot agree to recommend that in the present 
circumstances lethal injection should be substituted for hanging as the method of judicial execution 
in this country. If we could have been satisfied that executions could be carried out in this way 
quickly, painlessly and decently in all cases, we should have recommended its adoption 
unanimously. But we are bound to conclude from our expert evidence that there is not at present a 
reasonable certainty of this. We do, however, recommend, unanimously and emphatically, that the 
question should be periodically examined, especially in the light of progress made in the science of 
anaesthetics, with a view to a change of system being proposed to Parliament as soon as it can be 
shown that there are no longer any grounds for the doubts that now deter us from recommending 
it.”). 
125. Id. at 257–59. 
126. See id. at 258–59. 
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performed with dignity, solemnity, speed, and certainty,” might make 
sense in the future.127 
Notwithstanding these earlier qualms about execution with lethal 
injection, along with the views of its own state senators that there was a 
need for more research before lethal injection should be adopted,128 the 
State of Oklahoma adopted a lethal injection protocol in 1977.129 Jay 
Chapman, the state’s medical examiner, was asked by a state legislator 
to develop a lethal injection protocol. Dr. Chapman initially replied that 
he “was an expert in dead bodies but not an expert in getting them that 
way.”130 Yet, Dr. Chapman first proposed that lethal injection could 
involve an “ultra-short-acting barbiturate in combination with a chemical 
paralytic.”131 In 1981, Chapman modified his initial proposal protocol to 
add a third drug, potassium chloride, thereby developing the three-drug 
protocol that became the standard for execution in the United States until 
recently.132 
B. More Recent Developments in Executions 
By 2008, all of the thirty-eight jurisdictions133 that permitted 
execution by lethal injection used the protocol Chapman developed and 
administered a sequence of three drugs intravenously.134 The first drug 
was a dose of sodium thiopental that was given in a lethal dose. But this 
dose takes a relatively long time to result in death, and the drug was not 
expected to cause death before the rest of the drugs take effect. Rather, it 
was administered for its anesthetic effects. The second chemical was 
pancuronium bromide, a neuromuscular blocking agent that paralyzes 
the inmate. This chemical was used to further the state’s interest in 
dignity by making the dying process appear serene.135 However, 
127. Id. at 259. 
128. John Greiner, Drug Execution Plan Suffers Senate Setback, DAILY OKLAHOMAN, Feb. 16, 
1977, at 16. 
129. OKLA. DEP’T OF CORR., NO. P-090901, OKLAHOMA POLICY STATEMENT, PROCEDURES FOR 
CARRYING OUT THE DEATH SENTENCE (1978) (citing OKLA. DEP’T OF CORR., NO. P-090900, 
OKLAHOMA POLICY STATEMENT, PROCEDURES FOR CARRYING OUT THE DEATH SENTENCE (1977)). 
130. Denno, supra note 99, at 65–66. 
131. Id. at 66–67. 
132. Id. at 74. 
133. TRACY L. SNELL, U.S. DEP’T OF JUSTICE, BUREAU OF JUSTICE STATISTICS, CAPITAL 
PUNISHMENT, 2008—STATISTICAL TABLES, at 5 tbl.2 (2009), available at http://www.bjs.gov/ 
content/pub/pdf/cp08st.pdf.  
134. Shah, supra note 32, at 1105. 
135. Baze v. Rees, 553 U.S. 35, 49 (2008). 
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pancuronium bromide also makes problems in the administration of the 
first drug difficult, if not impossible, for witnesses to detect.136 Finally, 
potassium chloride was administered to cause death by cardiac arrest.137 
If everything went according to plan, the first drug anesthetized the 
inmate from pain, the second drug prevented the inmate’s spasms or 
death throes from disturbing the audience, and the third drug caused 
death quickly. If the anesthetic was not administered correctly, however, 
all parties now agree that the inmate would experience excruciating 
suffering before death.138 
Some examples of executions that seemed to go poorly raised concern 
about the three-drug protocol. In Florida, Governor Jeb Bush 
temporarily halted executions in the state after Angel Diaz’s botched 
execution in December of 2006.139 An autopsy revealed that the lethal 
injection administered to Mr. Diaz was not inserted into his veins, but 
rather into the soft tissue of his arms.140 He sustained chemical blisters 
of a foot in length on both of his arms, and because the effect of the 
anesthesia administered was likely diluted, he seemed to have 
experienced agonizing pain.141 
In California, a court reviewing lethal injection evidence was troubled 
by the fact that “anomalies in six execution logs raise substantial 
questions as to whether certain inmates may have been conscious” 
during the procedure.142 These outcomes were concerning because when 
an inmate is not sufficiently anesthetized before lethal drugs are 
administered, “the inmate may suffer excruciating suffocation.”143 Based 
on this and other evidence, executions in California were stayed by a 
district court judge.144 Similar problems arose all over the country.145 In 
136. Denno, supra note 99, at 55–56. 
137. Ty Alper, Lethal Incompetence: Lethal Injection Litigation Is Exposing More Than 
Torturous Executions, THE CHAMPION, Sept.–Oct. 2006, at 41. 
138. Baze, 553 U.S. at 53 (“It is uncontested that, failing a proper dose of sodium thiopental that 
would render the prisoner unconscious, there is a substantial, constitutionally unacceptable risk of 
suffocation from the administration of pancuronium bromide and pain from the injection of 
potassium chloride.”). 




141. Chris Tisch, Doctor: Killing Flawed at Start, ST. PETERSBURG TIMES (Feb. 12, 2007), 
http://www.sptimes.com/2007/02/12/news_pf/State/Doctor__Killing_flawe.shtml; see also Crair, 
supra note 139. 
142. Morales v. Tilton, 465 F. Supp. 2d. 972, 980 (N.D. Cal. 2006). 
143. Ty Alper, supra note 137, at 41. 
144. Order Following Remand at 2, Morales v. Cate, No. 5-6-cv-219-JF-HRL (N.D. Cal. 2010).  
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2007, the U.S. Supreme Court granted certiorari to Baze v. Rees and 
seemed poised to address this controversy.146 However, the Court found 
that there was insufficient reason to conclude that Kentucky’s lethal 
injection protocol was unconstitutional, though it could reach agreement 
on little else.147 
Since that time, much has changed. States are facing drug shortages, 
drug embargoes, and ethical restrictions that may prevent qualified 
experts from becoming involved in executions. The FDA recently began 
regulating the importation of drugs for use in executions.148 Drug 
manufacturers, particularly those based in Europe, have raised concerns 
that exportation of their drugs may result in those drugs being used for 
executions. These manufacturers have either stopped selling their drugs 
in American markets or specifically prohibited the use of their drugs in 
executions.149 Experiencing greater difficulties in obtaining drugs that 
are already on the market for lethal injection purposes, state departments 
of corrections are turning to compounding pharmacies to obtain the 
drugs needed.150 Compounding pharmacies are pharmacies that make 
drugs to fill individual prescriptions, as opposed to the bulk 
manufacturing of drugs by pharmaceutical companies.151 The production 
of drugs by compounding pharmacies has traditionally been much more 
lightly regulated than the manufacturing of most prescription 
medications.152 The use of compounding pharmacies, however, has 
undergone increased scrutiny after sixty-four deaths were attributed to 
the use of contaminated drugs produced at the New England 
145. See Denno, supra note 99, at 76–77. 
146. Baze v. Rees, 551 U.S. 1192 (2007). 
147. Linda Greenhouse, Justices to Enter the Debate Over Lethal Injection, N.Y. TIMES (Sept. 
26, 2007), http://www.nytimes.com/2007/09/26/washington/26lethal.html?_r=0. 
148.  Kevin O’Hanlon, Company Recalls Nebraska’s Lethal Injection Drug, LINCOLN J. STAR 
(May 9, 2012), http://journalstar.com/news/local/crime-and-courts/company-recalls-nebraska-s-
lethal-injection-drug/article_3694f11a-a844-5955-ae7f-a5d9253ed10a.html.  
149. See Proposal for a Regulation of the European Parliament and of the Council, COM (2014) 
1 final (Jan. 1, 2014), available at http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri= 
COM:2014:0001:FIN:EN:PDF (prohibiting the exportation of drugs for use in capital punishment). 
Additionally, manufacturers in the United States have made anti-capital punishment statements and 
indicated that they will not sell drugs for use in executions. See, e.g., Anti-Capital Punishment 
Statement, SAGENT PHARMACEUTICALS, http://www.sagentpharma.com/contactmenu/anti-capital-
punishment-statement.html (last visited Jan. 5, 2015). 
150. Denno, supra note 27, at 1366. 
151. Matt McCarthy, FDA Inspections Find Unsafe Practices in Compounding Pharmacies, 346 
BMJ 1 (2013). 
152. See id. 
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Compounding Center.153 Congress recently passed a law heightening 
regulatory requirements for compounding pharmacies and for the 
reporting of adverse events from their products.154 This law also creates 
a new category of regulated entities (“outsourcing facilities”) that 
compounding pharmacies can fall under.155 If a compounding pharmacy 
voluntarily registers with the FDA as an “outsourcing facility,” certain 
FDA requirements would be relaxed, but FDA inspections of their 
facilities would be permitted.156 It is not clear at present whether this law 
will also apply to drugs obtained from compounding pharmacies that are 
used in executions. 
While many states are actively engaged in modifying their lethal 
injection protocols, these protocols are not uniform across the country. 
Different states use different drugs. Some states use midazolam, which is 
used for treatment of seizures and as premedication for anesthesia, and 
pentobarbital, a barbiturate commonly used to euthanize animals and to 
treat seizures in humans.157 Eleven states have modified their protocols 
to allow for the possibility of execution with a single drug.158 Because of 
drug shortages, sixteen states substituted the drug pentobarbital for 
sodium thiopental, the anesthetic they previously used.159 Missouri also 
switched to a one-drug protocol and initially selected the drug propofol, 
but then later revised its execution procedures to require pentobarbital as 
well.160 Even after its protocol was determined to be constitutional in 
Baze, Kentucky switched to a one-drug protocol, with a back-up of a 
153. Stephen Barlas, New Congressional Bill Attempts to Aid Pharmacy Response to Drug 
Shortages, 39 P&T 51, 51 (2014). 
154. Drug Quality and Security Act, H.R. 3204, 113th Cong. (2013).  
155. Erika Lietzan & Mingham Ji, Pharmacy Compounding After the Drug Quality and Security 
Act, 26 HEALTH LAWYER 4–5 (2014). 
156. Id. However, there is some concern that by passing this law, Congress may have actually 
undermined the FDA’s regulatory authority because compounding pharmacies are not required to 
register with the FDA, and FDA already had regulatory tools that it could apply to compounding 
pharmacies that are taken away if compounding pharmacies register as outsourcing facilities. Id. at 
5. Nonetheless, the new law does clarify that FDA has some authority over compounding 
pharmacies, and this authority was arguably less clear before the law was passed. 
157. Paul W. Shaw, Federal Legislative Response to the Controversy over Drug Compounding, 7 
J. HEALTH & LIFE SCI. L. 84, 84 (2014). 
158. See Denno, supra note 27, at 1359 chart 4. 
159. See id. 
160. See MO. DEP’T OF CORR., PREPARATION AND ADMINISTRATION OF CHEMICALS FOR LETHAL 
INJECTION (2013) (on file with Washington Law Review) State by State Lethal Injection, DEATH 
PENALTY INFO. CTR., http://www.deathpenaltyinfo.org/state-lethal-injection (last visited June 2, 
2014). 
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two-drug protocol if necessary.161 
In at least some cases, these changes have seemed to contribute to 
botched executions. In October 2012, an execution in South Dakota used 
compounded pentobarbital that was later found to be contaminated with 
fungus. Eric Robert, the inmate executed with the adulterated drug, had 
his eyes open throughout the execution, raising concern that he may not 
have been adequately anesthetized.162 
The process of experimentation is well illustrated by what has 
happened in Ohio. Ohio first allowed lethal injection in 1993 as a 
possible alternative to electrocution, and retired its electric chair and 
made lethal injection its sole method of execution in 2002.163 The 
protocol in Ohio has changed several times. One of the most significant 
changes occurred in 2009. Ohio switched to a one-drug protocol (with a 
back-up plan) after an Ohio state court judge determined that the three-
drug protocol violated Ohio’s statutory requirement for a “quick and 
painless death.”164 Although this change was a big departure from prior 
protocols, it also was likely to decrease the risks of execution, and it 
introduced an option that inmates had been requesting and may 
reasonably have chosen in an informed consent process.165 The State 
then switched from one barbiturate to another after a drug shortage, and 
then moved to a two-drug protocol involving midazolam after the 
Danish manufacturer of the barbiturate refused to sell it for use in 
executions.166 In 2013, Ohio introduced another new protocol that 
included many changes from the previous protocols, including: (1) the 
intravenous administration of two execution drugs—hydromorphone and 
midazolam; (2) the use of compounded drugs; and (3) the availability of 
multiple options if the preferred method of execution will not work for 
some reason, including the possibility of intramuscular injection, which 
no other state has used.167 In this lethal injection protocol, the state also 
added a quality assurance review with a designated official empowered 
161. 501 KY. ADMIN. REGS. 16:330 (2012). 
162. South Dakota Covers Up Source of ‘DIY’ Death Penalty Drugs Ahead of Execution, 
REPRIEVE (Oct. 30, 2012), http://www.reprieve.org.uk/press/2012_10_30_South_Dakota_ 
execution_drugs. 
163. Capital Punishment in Ohio, OHIO DEP’T OF REHABILITATION & CORRECTION, 
http://www.drc.ohio.gov/public/capital.htm (last visited Jan. 5, 2015). 
164. State v. Rivera, Nos. 04CR065940, 05CR068067, at 5 (Ohio Cnty. Ct. C.P. June, 10, 2008). 
165. See infra Part IV. 
166. Ben Crair, Exclusive Emails Show Ohio’s Doubts About Lethal Injection, NEW REPUBLIC 
(Aug. 17, 2014), http://www.newrepublic.com/article/119068/exclusive-emails-reveal-states-
worries-about-problematic-execution. 
167. Denno, supra note 27, at 1354–58. 
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to review the conduct of executions in consultation with others 
(including a “properly trained medical person”), but it is not clear 
whether or how this is being implemented.168 In January 2014, an 
execution was conducted under Ohio’s modified protocol that did not go 
according to plan. Dennis McGuire’s execution lasted twenty-six 
minutes, during which time he gasped, snorted, and appeared to be 
struggling for breath.169 
Notably, the introduction of several untested components at once 
makes it more difficult to determine what is responsible for problematic 
executions.170 As another example, Florida was the first state to use 
midazolam, and did so in an execution that lasted much longer than 
average. Although the warden checked to confirm that the inmate was 
unconscious prior to authorizing the administration of the next drug, the 
inmate made several movements after the warden made this 
determination. To witnesses it appeared that he was not fully 
anesthetized.171 The drugs used were not based on prior experience in 
animal euthanasia—indeed, there was very limited evidence for this 
dramatic change.172 Some lethal injection experimentation today 
demonstrates a willingness to expose inmates to drugs that have never 
been used in this way before, even though the risks are highly uncertain. 
Like the troubling historical experiments I described in Part I, lethal 
injection experimentation has not been based on the kind of careful 
preparation and evidence gathering that should be done before exposing 
humans to new and uncertain risks. As I will explain below, using new 
drugs in humans requires a rigorous evidentiary foundation—one that 
lethal injection lacks. 
III. FEATURES OF LETHAL INJECTION INVOLVING 
RESEARCH 
In this section, I argue that by testing novel drugs, drug combinations, 
and doses in executions to see what will work, states are conducting a 
type of biomedical research, albeit one that is poorly designed and lacks 
168. STATE OF OHIO DEP’T OF REHAB. & CORR., ORC 2949.22, 2949.25 (Oct. 10, 2013) (on file 
with Washington Law Review). 
169. Holschuh, supra note 30. 
170. Lazare, supra note 32.  
171. Daily Mail Reporter & Reuters, William Happ Executed: Florida Executes Man Using 
Untried Lethal Injection Drug, DAILY MAIL (Oct. 15, 2013, 6:20 PM), http://www.dailymail.co.uk/ 
news/article-2462115/William-Happ-executed-Florida-executes-murderer-using-untried-lethal-
injection-drug.html. 
172. Alper, supra note 137, at 41–42. 
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a solid basis in the available evidence. The flimsy evidence base for the 
use of various drugs, drug combinations, and doses makes it very 
difficult to predict the outcome of most executions today. That 
executions by lethal injection involve poorly conceived research 
suggests that states should adopt the safeguards that have been 
developed for human subjects research for executions by lethal injection. 
Current approaches to execution by lethal injection have been conducted 
in a manner that allows for rigorous and independent oversight by 
experts on research, that permits subjects to provide informed consent to 
protect their own interests, and that minimizes risks where possible. 
Furthermore, states should either adopt approaches that do have a 
rigorous evidentiary basis, or, if that is not possible, conduct research 
that is scientifically rigorous. 
As I will further explain below, executions by lethal injection have 
some features of different categories of medical practice and innovation. 
Nevertheless, the most concerning features of experimental executions 
are the untested uses of new drugs, drug combinations, and dosages that 
can be understood as risky, poorly conceived research. 
It is useful to look at lethal injection executions in this way because 
scholars of research ethics and regulation have already thought through 
related issues in the context of medical research and have designed 
structures and safeguards to promote the autonomy, safety, and ethics of 
research subjects. Importing research protections to the lethal injection 
context may help reduce the number of error-prone and haphazard 
executions that are receiving considerable public scrutiny. 
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A. Lethal Injection Executions as Involving Non-validated Practice 
Some aspects of lethal injection experimentation involve the use of 
drugs and interventions that do not have a rigorous evidence base that 
assures states they will safely and effectively cause death. These features 
of lethal injection can be thought of as non-validated medical practice. 
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Non-validated practice involves using an intervention that is new or 
untested, without good reason to believe it will work.173 As was 
previously discussed, the Commission grappled with this distinction 
while writing The Belmont Report and recommended that non-validated 
approaches “should be . . . made the object of formal research at an early 
stage in order to determine whether they are safe and effective.”174 
Similarly, the World Medical Association’s Declaration of Helsinki, an 
influential international code of ethics, states: “Medical research 
involving human subjects must conform to generally accepted scientific 
principles, be based on a thorough knowledge of the scientific literature, 
other relevant sources of information, and adequate laboratory and, as 
appropriate, animal experimentation.”175 The practice of medicine 
improves by first testing novel agents in animals and in vitro, and then 
slowly introducing them in humans.176 To the extent that execution by 
lethal injection involves entirely novel uses of experimental medications, 
reform of lethal injection should involve conducting careful and 
systematic research. 
The scientific paradigm governing the adoption of new interventions 
was not used for lethal injection,177 even though the first three-drug 
protocol was invented by a physician who had doubts about whether it 
would actually work,178 and the first state legislature to adopt a lethal 
injection protocol was concerned about the lack of sufficient research on 
lethal injection. Preliminary animal and laboratory research and 
extensive experience of euthanizing animals have not been appropriately 
translated into executions of lethal injection in humans.179 For instance, 
paralytic agents like pancuronium bromide are not used and are actually 
condemned as inhumane by veterinary and animal welfare experts for 
fear they might mask an animal’s suffering.180 Significantly, the state of 
Texas rejected advice from a veterinarian about the use of single-drug 
protocols, used to euthanize animals, for fear the public would object to 
173. See THE BELMONT REPORT, supra note 69, at 3–4. 
174. Id. at 4.  
175. Declaration of Helsinki, para. 21, June 1964, available at http://www.wma.net/en/ 
30publications/10policies/b3/. 
176. Carl Cohen, The Case for the Use of Animals in Biomedical Research, 315 NEW ENG. J. 
MED. 865, 865–69 (1986). 
177. John Greiner, Drug Execution Plan Suffers Senate Setback, DAILY OKLAHOMAN, Feb. 16, 
1977, at 16. 
178. Denno, supra note 99. 
179. Ty Alper, Anesthetizing the Public Conscience: Lethal Injection and Animal Euthanasia, 35 
FORDHAM URB. L.J. 817, 835–37 (2008). 
180. Id. at 837. 
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treating people as we treat animals.181 
One way to move to a more evidence-based approach is to draw on 
related evidence and experience to develop protocols that one can have a 
reasonable degree of confidence will work. In particular, states could 
more carefully extrapolate from animal euthanasia protocols or 
euthanasia protocols for humans developed in other jurisdictions. 
Drawing from existing evidence is especially important when there are 
ethical concerns about randomizing participants to different approaches 
to collect data about their relative merits, as may be true for research to 
develop safe and effective methods of execution. Gathering 
observational data and any available data from other, related fields to 
improve an approach over time may sometimes be the best that can be 
done. There is extensive experience with animal euthanasia that has not 
been translated to the lethal injection context.182 This experience would 
rule out the use of the three-drug cocktail, and may suggest adoption of 
one-drug protocols. For drugs that have sufficient animal and laboratory 
data already on relevant clinical experience, there are still questions 
about how to translate those data into the use of the drugs for lethal 
injection in humans. Nevertheless, the risks of the use of these drugs are 
much better characterized, and much less than the risks associated with 
drugs that are in widespread use in executions by lethal injection today. 
There is also some clinical experience with drugs that could be used 
for lethal injection protocols in other jurisdictions. Oregon, the 
Netherlands, Belgium, and other jurisdictions have experience with 
physician-assisted suicide and euthanasia, and have developed protocols 
over time to ensure death can occur humanely. These may be the only 
other examples of medical practice that involve interventions used to 
cause death.183 Justice Alito’s opinion in Baze attempted to cast doubt on 
the use of one-drug protocols by citing a study that showed that a small 
percentage of patients receiving one-drug protocols do not die.184 But 
one-drug protocols do eliminate the risk of excruciating pain, so more 
doses of the drug can be given as a back-up plan without raising concern 
about the risk that the protocol will not work.185 Over time, the 
experiences of physicians in administering these protocols in physician-
181. Id. at 817. 
182. See id. at 817–18.  
183. Overview of Euthanasia, KNMP, http://www.knmp.nl/medicijnen-zorgverlening/overig/ 
euthanasia (last visited Feb. 21. 2014 ) (Dutch Professional Trade Association of Pharmacists). 
184. See Baze v. Reese, 553 U.S. 35, 68 (2008) (Alito, J., concurring). 
185. Eric Burger, Lethal Injection and the Problem of Constitutional Remedies, 27 YALE L. & 
POL’Y REV. 259, 317–18 (2009). 
 
                                                     
08 - Shah - final.docx (Do Not Delete) 4/13/2015  11:51 AM 
2015] EXPERIMENTAL EXECUTION 181 
assisted suicide in the Netherlands have been systematically collected 
and published to improve the process.186 However, one key problem in 
translating from protocols used in the Netherlands is that these protocols 
are intended to be administered with physicians overseeing the process. 
Given the considerable controversy over physician participation in 
executions by lethal injection,187 it is not clear these protocols can be 
directly translated for use in American executions. 
Alternatively, states could conduct preclinical laboratory and animal 
testing of drugs that have not been used to cause death, and develop 
some of the evidence needed to be able to justify the use of these drugs 
in humans. Statistical methods are necessary to determine how large 
trials should be to evaluate the safety and efficacy of lethal injection 
protocols, and whether a particular design (e.g., a control arm) is 
necessary. This option would require the assistance of individuals with 
expertise in conducting clinical research and could not be done by 
members of state departments of corrections alone. 
However, there may be other barriers that prevent states from moving 
to protocols that are based in evidence from animal euthanasia. For 
example, one-drug protocols may be difficult to implement in some 
states that are having difficulty obtaining certain drugs. Leaving aside 
the relatively recent drug shortages and embargoes, it is puzzling why 
state departments of corrections have not been systematic and careful in 
attempting to improve such a controversial procedure. One charitable 
interpretation is that prison officials may be unaware of scientific 
methods, and the many constraints on the participation of medical 
personnel in executions have prevented states from obtaining good 
advice. Another possibility is that the lack of any systematic oversight 
by courts on lethal injection procedures, at least until fairly recently, has 
encouraged states to be as conservative as possible and stick to the three-
drug protocol in an effort to avoid further litigation that might be 
prompted by changes to protocols. The least charitable interpretation 
may be that those involved in developing execution procedures, much 
like the researchers who first began experimenting on prisoners, place 
little value on how they treat someone who has been sentenced to be 
186. Pieter V. Admiraal, [The responsible performance of euthanasia; observations on the 
discussion of the subject] [Article in Dutch], 127 Ned Tijdschr Geneeskd, 964, 964 (May 28, 1983); 
see also Personal Communication with Annemieke Horikx, Royal Dutch Society of Pharmacy 
(KNMP) (May 12, 2014). 
187. Compare Robert D. Truog, I. Glenn Cohen, & Mark A. Rockoff, Physicians, Medical 
Ethics, and Execution by Lethal Injection, 311 J. AM. MED. ASS’N 2375 (2014), with Lawrence 
Nelson & Brandon Ashby, Rethinking the Ethics of Physician Participation in Lethal Injection 
Execution, HASTINGS CTR. REP., May–June 2011, at 28–29. 
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executed. State departments of corrections therefore may have little 
incentive to proceed cautiously, except in the sense that executions do 
not appear inhumane and disturbing to the general public. 
B. Lethal Injection as Involving Research 
In this Section, I analyze the extent to which current approaches 
involve medical research. When lethal injections expose inmates to 
uncertain risks of drugs that lack solid evidence for use in executions, 
this activity is a type of research that is neither well designed nor 
systematic. Rather, it is conducted in an attempt to learn how to conduct 
future executions on other death row inmates. All states conducting 
executions have inmates on death row, borrow and learn from one 
another’s experiences, and tend to change their protocols by adopting the 
same new drugs around the same time.188 This suggests that states are 
making modifications and experimenting with the goal of producing 
knowledge from each individual execution to improve future executions. 
There are several different regulatory definitions of medical research, 
ranging from more to less restrictive.189 The narrowest definitions, like 
the definition used in the Department of Health and Human Services 
Regulations,190 fail to capture experimentation that is poorly designed 
and not systematic. The broader definitions, like those used in the FDA’s 
investigational new drug regulations and in state statutes and department 
of corrections policies, more clearly apply to many different types of 
research, including experimental execution. I argue below that FDA 
regulations are the most appropriate to apply, but also that there are 
barriers to enforcing any of these regulations. 
  
188. Denno, Lethal Injection Chaos Post-Baze, supra note 27, at 1341 chart 1, 1358 chart 3.  
189. See infra tbl.2.  
190. 45 C.F.R. § 46.102(d) (2014). But see 21 C.F.R. § 56.102(c) (2014) (defining “clinical 
investigation,” which the FDA considers to be synonymous with research, as “any experiment that 
involves a test article and one or more human subjects, and that either must meet the requirements 
for prior submission to the FDA . . . or the results of which are intended to be later submitted to, or 
held for inspection by, the FDA as part of an application for a research or marketing permit”). 
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Definition of Research 
DHHS Regulations, 





testing and evaluation, 




FDA IND Regulations Any use of a drug, 
except for the use of a 
marketed drug in the 
course of medical 
practice, in which a 
drug is administered to 
one or more human 
subjects 
State Statutes & 
Department of 
Corrections Policies 
Much variation; many 
simply prohibit “the use 






Although no court has directly addressed this issue, several different 
regulations governing research might apply to execution by lethal 
injection: (1) the Department of Health and Human Services (DHHS) 
regulations governing research on prisoners; (2) the research regulations 
of the Bureau of Prisons; (3) state departments of corrections regulations 
governing research on prisoners; and (4) the FDA’s Investigational New 
Drug (IND) regulations. I discuss these regulations in turn, and conclude 
that the three types of regulations that are most applicable are state, 
Bureau of Prisons, and FDA regulations. Bureau of Prisons and state 
regulations may impose helpful safeguards, but may also make it 
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applied according to a plain text reading. Finally, the FDA regulations 
are probably the most appropriate for regulating lethal injection 
experimentation, but the FDA may be reluctant to participate in review 
of lethal injection executions, and it would be difficult for courts to 
compel the agency to act. 
First, both the DHHS regulations governing research on prisoners and 
the Bureau of Prisoners regulations would likely not apply to lethal 
injection experimentation. The DHHS regulations apply only to research 
funded by the federal agencies that have signed on to those 
regulations.191 However, some states do reference the DHHS regulations 
in their state regulations governing research on prisoners.192 Those states 
may have difficulty continuing lethal injection research without 
addressing the safeguards discussed in Part VI, below. Additionally, the 
DHHS regulations define research narrowly as “a systematic 
investigation, including research development, testing and evaluation, 
designed to develop or contribute to generalizable knowledge.”193 To the 
extent that lethal injection executions are not systematically conducted, 
they may not fit this definition. Significantly, the regulations require that 
the research risks must be “commensurate with risks that would be 
accepted by nonprisoner volunteers”—which makes it hard to imagine 
that lethal injection research could be approved under these regulations, 
even if they did apply.194 
As I have argued elsewhere, state and department of corrections 
regulations in several states could severely restrict or prohibit current 
approaches to executions by lethal injection.195 The Bureau of Prisons 
regulations apply to research conducted within the Bureau of Prisons, 
either by external researchers or by employees of the bureau.196 These 
Bureau of Prisons regulations refer to the definition used in the DHHS 
191. Federal Policy for the Protection of Human Subjects (‘Common Rule’), U.S. DEP’T HEALTH 
& HUMAN SERVS., http://www.hhs.gov/ohrp/humansubjects/commonrule/ (last visited Jan. 5, 2015). 
Institutions that receive federal funding for research typically are required to sign Federal Wide 
Assurances (FWAs), in which they promise that all research conducted by their institution will 
abide by the protections in the DHHS regulations. If a State’s Departments of Corrections has an 
FWA, then it is possible that the DHHS regulations should be applied to lethal injection 
experimentation, and that the Office for Human Research Protection has the authority to enforce 
deviations from those regulations.  
192. See, e.g., Research Guidelines, N.C. DEP’T OF CORR. (Jan. 21, 2015), 
https://www.ncdps.gov/Index2.cfm?a=000003,002391,002412,002456. 
193. 45 C.F.R. § 46.102(d). 
194. 45 C.F.R. § 46.305(a)(3)–(4). 
195. See Shah, supra note 32. 
196. 28 C.F.R. § 512.10 (2014). 
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regulations governing research that was previously mentioned, and also 
prohibit “medical experimentation, cosmetic research, or pharmaceutical 
testing.”197 Although the definition of research referenced in these 
regulations is relatively narrow, the prohibition of medical 
experimentation is much broader. As I argued in a previous paper, in the 
absence of creative statutory interpretation, broad prohibitions on 
medical experimentation or pharmaceutical testing would seem to rule 
out lethal injection experimentation altogether.198 The additional 
restrictions in the Bureau of Prisons regulations include that risks to 
subjects have to be minimized, the risks must be “reasonable in relation 
to anticipated benefits,” “the selection of subjects within any one 
institution must be equitable,” and informed consent is generally 
required to be obtained and documented.199 One problem with applying 
these regulations to executions is that the Bureau of Prisons may not be 
amenable to such a reading of their regulations, and may be more 
sympathetic to arguments that executions do not involve the conduct of 
experimentation or research. 
A recent paper argues that the FDA’s regulatory authority likely 
extends to reviewing executions by lethal injection.200 The FDA has 
authority to review new drugs and protect patients and research subjects 
through its Investigational New Drug (IND) regulations.201 The IND 
regulations apply broadly to the use of interventions without a solid 
evidence base, and use the following definition of research: “Clinical 
investigation means any experiment in which a drug is administered or 
dispensed to, or used involving, one or more human subjects. For the 
purposes of this part, an experiment is any use of a drug except for the 
use of a marketed drug in the course of medical practice.”202 As an 
example of the broad reach of these regulations, the FDA has previously 
asserted that the IND regulations would cover human cloning.203 The 
197. 28 C.F.R. § 512.11(a)(3). 
198. Shah, supra note 32, at 1111. 
199. 28 C.F.R. § 512.11(a)(4). 
200. See JOHNS HOPKINS CLINIC FOR PUB. HEALTH L. & POL’Y, supra note 32, at 1–3. The 
authors note that there are jurisdictional challenges because actions to enforce the Food, Drug & 
Cosmetic Act (FDCA) must be brought by the government, but argue that death row inmates may 
be able to argue for enforcement on the basis of their Fourteenth Amendment due process rights or 
as an Eighth Amendment challenge. Id. at 3–4. 
201. Richard A. Merrill, Human Tissues and Reproductive Cloning: New Technologies Challenge 
FDA, 3 HOUS. J. HEALTH L. & POL’Y 1, 5 (“The protection of study subjects is a central objective of 
the law that permits FDA to approve INDs and of the Agency’s own standards and procedures.”). 
202. 21 C.F.R. § 312.3(b) (2014).  
203. Rick Weiss, Human Clone Research Will Be Regulated: FDA Asserts It Has Statutory 
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definition of research in the IND regulations is much more expansive 
than the definition used in the DHHS regulations.204 It would seem to 
require that states either define their activities as medical practice or 
submit an IND application to the FDA. As noted earlier, many states 
expressly define their activities as outside the scope of medical practice. 
Even for states that do not define lethal injection executions as outside 
the practice of medicine, to the extent they are conducting medical 
research, they are clearly operating not engaged in the practice of 
medicine. 
Under the IND regulations, sponsors and researchers have to submit 
an application of their research protocol to the FDA for prior review of 
safety, efficacy, and scientific merit. The FDA would have the authority 
to insist upon review by an institutional review board (IRB) or to 
suspend the activity by placing the investigation on what is known as a 
“clinical hold.”205 Under the regulations, if a state submitted a proposed 
protocol to the FDA and fulfilled the regulatory requirements thirty days 
before an execution, and the FDA failed to act, then the state could 
proceed with the execution.206 
The FDA might be reluctant to take on this review. First, there is lack 
of clarity about the right standard of review and how the FDA would 
apply its own statutory authority to executions. Another problem is that 
the FDA is required to determine whether drugs are safe and effective 
under the Federal Food, Drug, and Cosmetic Act,207 which may be an 
impossible standard for executions to meet. In FDA v. Brown & 
Williamson Tobacco Corporation,208 the Supreme Court held that the 
FDA could not assert its authority over tobacco products because the 
FDA’s requirement to ensure drugs and devices are safe simply could 
Authority to Regulate Attempts at Human Cloning, WASH. POST, Jan. 20, 1998, at A1. (quoting the 
Lead Deputy Commissioner Michael Friedman’s claim that the FDA had the authority to regulate 
cloning through the IND regulations based on “serious health and safety issues” for the mother and 
cloned fetus). 
204. 21 U.S.C. § 355 (2012). 
205. 21 U.S.C. § 355(i)(3)(A). 
206. JOHNS HOPKINS CLINIC FOR PUB. HEALTH L. & POL’Y, supra note 32, at 12.  
207. 21 C.F.R. § 312.22(a) (2014) (“FDA’s primary objectives in reviewing an IND are, in all 
phases of the investigation, to assure the safety and rights of subjects, and, in Phase 2 and 3, to help 
assure that the quality of the scientific evaluation of drugs is adequate to permit an evaluation of the 
drug’s effectiveness and safety. Therefore, although FDA’s review of Phase 1 submissions will 
focus on assessing the safety of Phase 1 investigations, FDA’s review of Phases 2 and 3 
submissions will also include an assessment of the scientific quality of the clinical investigations 
and the likelihood that the investigations will yield data capable of meeting statutory standards for 
marketing approval.”). 
208. 529 U.S. 120 (2000) 
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not be met by regulating tobacco products—the FDA would have to take 
them off the market.209 Because Congress had “foreclosed the removal 
of tobacco products from the market,” the Court found that FDA 
regulation of tobacco products would “plainly contradict Congressional 
policy.”210 Although one could argue that executions cannot be 
conducted in a safe manner since the goal of an execution is to cause 
death, what the FDA regulates depends on how the clinical investigation 
is defined. To the extent that the goal of clinical investigations in 
executions would be to determine whether the use of certain drugs 
within executions could decrease the risks of suffering, the FDA could 
presumably approve that research. Precluding the use of some drugs as 
unacceptably risky would also not clearly contradict Congressional or 
state policy. Therefore, the FDA does have room to regulate executions 
without banning them altogether, and would not necessarily have to 
contradict federal or state policy to do so. 
Additionally, the FDA routinely judges the safety of drugs where 
those drugs pose both risks and benefits to the individuals who are 
taking them. But there is no clear benefit to inmates to undergo 
executions, so the risks and benefits would have to be evaluated in some 
other way. Given that the Supreme Court has not settled on one standard 
for determining when the risks associated with lethal injection would be 
unconstitutional,211 it may be very difficult for the FDA to assess 
whether the risks associated with lethal injection are acceptable. Yet, as I 
argue below, the research regulations do provide clear guidance on the 
need to minimize risks, which is one area where the FDA’s considerable 
expertise could be invaluable. 
If the FDA decides not to enforce the IND regulations, whether the 
agency can be compelled to act is not settled. It depends on whether the 
agency’s decision was discretionary or mandatory. In Heckler v. 
Chaney,212 the U.S. Supreme Court reviewed the FDA’s decision not to 
exercise its authority under the Food, Drug, and Cosmetic Act213 to 
perform enforcement actions such as reviewing the safety and efficacy 
of lethal injection drugs being distributed in interstate commerce, 
affixing warning labels to the drugs, and seizing drugs that were to be 
used in executions.214 The Supreme Court has explained that under the 
209. Id. at 135. 
210. Id. at 137–39. 
211. Baze v. Reese, 553 U.S. 35, 52 (2008). 
212. 470 U.S. 821, 824 (1985).  
213. 21 U.S.C. § 355 (2012). 
214. Heckler, 470 U.S. at 824. 
 
                                                     
08 - Shah - final.docx (Do Not Delete) 4/13/2015  11:51 AM 
188 WASHINGTON LAW REVIEW [Vol. 90:147 
Administrative Procedures Act, if an agency elects not to pursue that 
action and exercise its coercive power, the action is “presumptively 
unreviewable” by the courts.215 The particular decision to enforce the 
FDCA was committed to agency discretion by law, and the Court 
concluded that the presumption was not overcome in that case. 
Deference to the FDA was warranted.216 On the other hand, in Cook v. 
FDA,217 the D.C. Circuit held that the FDA’s jurisdiction over the 
regulation of importation of lethal injection drugs into the country was 
not discretionary, but mandatory. The FDA was therefore required to 
inspect the importation of drugs and refuse admission to drugs that were 
adulterated, misbranded, or unapproved for use in the United States.218 
Importantly, the IND regulations require the sponsor of the research 
to submit an application to the FDA,219 suggesting that this may not be 
an action subject to discretion on the part of the sponsor of the research 
at least. This requirement on sponsors does not necessarily imply, 
however, that the FDA is required to enforce these regulations against 
departments of corrections who are failing to comply.220 Additionally, 
though the FDA can grant exemptions to IND requirements, to meet 
these exemptions, states would have to receive approval from an IRB 
and would also have to ensure that the way the drugs are being 
administered does not “significantly increase the risks” or “decrease the 
acceptability of the risks.”221 There is no indication that any of the states 
conducting lethal injection have received IRB approval, and it would be 
hard to argue that administration of anesthetic and paralytic drugs by 
non-medically trained prison officials could do anything but 
significantly increase the risks involved. 
There are, additionally, policy reasons why the FDA may be reluctant 
to regulate experimental executions and courts may find these reasons 
persuasive. For instance, in Heckler v. Chaney,222 the FDA 
Commissioner explained that the FDA decided not to exercise 
jurisdiction over lethal injection drugs because its jurisdiction over these 
215. Id. at 828–32. 
216. Id. at 837. 
217. 733 F.3d 1 (D.C. Cir. 2013). 
218. Id. at 10 (citing 21 U.S.C. § 381(a) (2012)). 
219. 21 C.F.R. § 312.1(a) (2014). 
220. 21 U.S.C. § 355(i) (2012). Note that citizens could petition the FDA to ask why the FDA is 
not enforcing IND regulations or failing to respond to a protocol submitted by a state department of 
correction under 21 U.S.C. § 10.30 (2012). 
221. 21 C.F.R. § 312.2(b)(iii). 
222. 470 U.S. 821 (1985). 
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drugs was not clear and capital punishment is a matter of criminal justice 
with which it should not interfere.223 He further stated that: 
Were FDA clearly to have jurisdiction in the area, moreover, we 
believe we would be authorized to decline to exercise it under 
our inherent discretion to decline to pursue certain enforcement 
matters. The unapproved use of approved drugs is an area in 
which the case law is far from uniform. Generally, enforcement 
proceedings in this area are initiated only when there is a serious 
danger to the public health or a blatant scheme to defraud. We 
cannot conclude that those dangers are present under State lethal 
injection laws, which are duly authorized statutory enactments 
in furtherance of proper State functions . . . .224 
The court in Cook v. FDA also took into account policy considerations 
that might give reason to respect an FDA decision not to act. The court 
noted that as a matter of statutory interpretation, courts can depart from 
the plain text if it would lead to an “absurd” result.225 In Cook, the court 
considered the FDA’s arguments that the agency was best positioned to 
determine how to allocate its scarce resources under this authority.226 
But the FDA’s inability to regulate every article imported into the 
country did not convince the court that the FDA should not examine the 
subset of drugs at issue in lethal injection executions. In sum, the FDA’s 
regulations are the most applicable, but there are several barriers to 
enforcing these regulations, particularly if the FDA is not willing to do 
so itself. State regulations, department of corrections policies, and the 
Bureau of Prisons regulations would also apply, though it would be 
difficult to approve experimental execution under these regulations. 
C. Lethal Injection as Involving Quality Improvement 
State departments of corrections explicitly indicate in some cases that 
their activities are a form of quality improvement or quality control. As I 
will argue below, the distinction between quality improvement and 
research does not have much normative significance, and I will not rely 
on it heavily in my analysis of what should be done about experimental 
executions. Nevertheless, it is worth explaining what aspects of 
executions might count as quality improvement to forestall potential 
223. Id. at 824. 
224. Id. at 824–25. 
225. Cook v. FDA, 733 F.3d 1, 9 (D.C. Cir. 2013) (citing United States ex rel. Totten v. 
Bombardier Corp., 380 F.3d 488, 494 (D.C. Cir. 2004)). 
226. Id. at 9. 
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objections. 
As an example of a state describing lethal injection modifications and 
the related data collection as quality control, Ohio explicitly labels a 
section of its protocol with the subtitle “Quality Assurance,” and has a 
designated Special Assistant for Execution Policy and Procedures. The 
Ohio protocol provides: “The Special Assistant shall evaluate the 
performance of the Execution Team, review the conduct of court-
ordered executions and report to the Director of the Department. His or 
her duties will consist of reviewing documentation, training, and 
professional qualifications, to ensure compliance with the written policy 
directive.”227 Quality control “is designed to bring about the immediate 
improvement of care in local settings,”228 typically by applying existing 
knowledge of practices that are within the standard of care. These 
modifications can happen at just one institution or several. The line 
between research and quality control typically turns on whether the 
results of the investigation are intended to improve local practice or to be 
disseminated more broadly—quality improvement is often characterized 
by the quick feedback of the findings into the same setting that was 
making the changes and studying them.229 Even if the State of Ohio is 
right to see its lethal injection experimentation as a form of quality 
assurance or quality control, whether it should have increased ethical 
safeguards depends on the level of risk. 
To the extent that these quality control activities involve high risks, 
the distinction between research and quality control is a distinction 
without a difference. Furthermore, scholarship on research ethics and 
regulations has begun to recognize that the classic distinctions between 
treatment, research, and quality control are eroding as data collection is 
increasingly a part of every medical encounter, and the important 
normative questions therefore are about the level of risk involved for the 
subjects of the data collection.230 As quality control activities involve 
increasing amounts of risk, the ethical restrictions on quality control 
activities come closer to those governing research, and informed consent 
is typically required.231 Since the normative value of distinguishing 
227. STATE OF OHIO DEP’T OF REHAB. & CORR., supra note 168. 
228. Mary A. Baily et al., The Ethics of Using QI Methods to improve Health Care Quality and 
Safety, HASTINGS CTR. REP., July–Aug. 2006, at S1, S29. 
229. Id. at S34. 
230. Nancy E. Kass et al., The Research-Treatment Distinction: A Problematic Approach for 
Determining Which Activities Should Have Ethical Oversight, HASTINGS CTR. REP., Jan.–Feb. 2013, 
at S4, S5; Emily A. Largent, Steven Joffe, & Franklin G. Miller, Can Research and Care Be 
Ethically Integrated?, HASTINGS CTR. REP., July–Aug. 2011, at 3738. 
231. See Kass et al., supra note 230, at S6–7. 
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lethal injection practices that might be appropriately considered quality 
control activities from those that have aspects of medical research is not 
clear, I will not rely on this distinction in this analysis. 
If the evidence that seven percent of all executions by lethal injection 
have been botched in some way is accurate, and if the risks associated 
with error involve excruciating pain and suffering, it seems likely the 
risks involved in execution by lethal injection are more than minimal 
and deserve increased ethical protections (namely, informed consent and 
independent review of the protocols). It is also relevant that prison 
officials who have difficulty obtaining the drugs needed for executions 
are turning to compounding pharmacies, given the extra risks associated 
with the drugs produced in compounding pharmacies.232 
In sum, by using untested drugs, drug combinations, and doses, 
executions by lethal injection involve poorly designed research. The 
regulations that most clearly apply to executions by lethal injection are 
FDA IND regulations, Bureau of Prisons regulations, and state laws and 
department of corrections policies that have expansive definitions of 
research. There may be significant barriers facing those who seek to 
enforce these regulations as they apply to experimental executions, as I 
have suggested above. However, the regulations do converge on several 
protections that have interesting implications for experimental 
executions. In the next section, I demonstrate how the safeguards that 
are common across the regulations would apply to lethal injection 
experimentation. 
IV. SPECIFIC ETHICAL AND REGULATORY SAFEGUARDS 
FOR LETHAL INJECTION EXECUTION 
There are three requirements common to all of the regulations 
described above that should be applied to experimental execution: (1) 
independent oversight, (2) risk minimization, and (3) informed 
consent.233 
A. Independent Oversight 
Perhaps the most important of the research protections, and the way to 
232. Jesse M. Boodoo, Compounding Problems and Compounding Confusion: Federal 
Regulation of Compounded Drug Products and the FDAMA Circuit Split, 36 AM. J.L. & MED. 220, 
221 (2010). 
233. See 45 C.F.R. § 46, subpart C (2014); 21 C.F.R. § 50 (2014); 28 C.F.R. § 512.10 (2014); 
Ezekiel J. Emanuel, David Wendler, & Christine Grady, What Makes Clinical Research Ethical? 
283 J. AM. MED. ASS’N 2701, 2701 (2000). 
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ensure that the other requirements are met, is independent expert review. 
Independent oversight of research helps ensure that research is sound, 
likely to yield generalizable results, and not unacceptably risky. A 
critical component of rigorous oversight is having relevant expertise. 
Prison officials cannot be allowed the discretion to experiment with 
biomedical interventions on prisoners without oversight. Officials 
devising execution protocols seek execution methods that courts will not 
view as involving cruel and unusual punishment and that do not raise 
public concern, but not necessarily methods that reduce risks as far as 
possible. One of the difficulties with the current system, as I will argue 
below, is that courts lack sufficient expertise to evaluate protocols and 
develop appropriate safeguards. 
There are at least four possible places where independent review of 
lethal injection protocols could be performed: (1) Institutional Review 
Boards (IRBs), (2) courts, (3) the FDA, and (4) a quality control panel 
set up specifically at the prison. Some commentators have argued that 
IRBs should review lethal injection protocols.234 IRBs are required to 
have at least five members, with at least one member whose expertise is 
scientific and at least one member from non-scientific background, and 
one member who is not affiliated with the institution.235 The research 
ethics literature is replete with criticism of IRBs for being overprotective 
and focused on informed consent above all else.236 Given how 
conservative IRBs are about the risks of research,237 it is safe to assume 
that no IRBs in the United States have experience reviewing research 
designed to result in death. Nevertheless, IRBs do have far more 
experience reviewing research than the courts, and the regulatory 
requirements are meant to ensure some degree of relevant expertise and 
independence from the institution. Thus, if there are IRBs that have 
extensive experience reviewing research that takes place in correctional 
settings, these IRBs might have the general expertise to evaluate lethal 
234. Koniaris et al., supra note 32. 
235. 45 C.F.R. § 46.107. 
236. Carol A. Heimer & JuLeigh Petty, Bureaucratic Ethics: IRBs and the Legal Regulation of 
Human Subjects Research, 6 ANN. REV. L. SOCIAL SCI. 601, 605–06 (2010) (“[M]uch of the 
literature on human subjects regulation asserts that IRBs have failed at the task of regulating human 
subjects research.”); Taimur Saleem & Umair Khalid, Institutional Review Boards—a Mixed 
Blessing, 4 INT’L ARCHIVES MED. 19, 20 (2011) (commenting that IRBs “represent an intrusion of 
bureaucracy and excessive red tape into medicine to the extent of being ‘frustrating’, ‘consternating’ 
and ‘paternalistic for the researchers”); see also Beth Azar, Ethics at the Cost of Research?, 
MONITOR ON PSYCHOL., Feb. 2002, at 38, 38. 
237. See Seema Shah et al., How Do Institutional Review Boards Apply the Federal Risk and 
Benefit Standards for Pediatric Research?, 291 J. AM. MED. ASS’N 476 (2004). 
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injection experimentation. Additionally, IRBs do sometimes use ad hoc 
subject matter experts in situations where the complexity of a research 
study requires additional input. 
Courts have, of course, already been involved in the process of 
evaluating lethal injection protocols. One problem with having courts 
review lethal injection protocols as research or quality control projects is 
they typically have less expertise in evaluating research. Some of the 
most prominent cases in which courts have made judgments pertaining 
to research studies have been criticized for the limited understanding of 
the justifications for and constraints on research.238 The limitations faced 
by courts are illustrated by the transcript of a hearing in the recent 
Arizona execution of Mr. Wood discussed in the introduction. Although 
the judge demonstrated impartiality and competence in running the 
proceedings, because he did not know or have ready access to 
information that brain death is incompatible with spontaneous breathing, 
or whether stopping the execution would minimize the amount of pain 
the inmate may have been suffering, the court’s ability to provide 
adequate oversight over the execution was compromised.239 
There are legal procedures for hearing and evaluating scientific 
evidence and expert testimony, including ensuring there is a zealous 
advocate to present and vet the appropriate evidence. But the current 
level of secrecy that many states are using with respect to their execution 
procedures and suppliers is incompatible with robust independent review 
of the research on lethal injection. If courts are not weighing evidence on 
whether a particular compounding pharmacy has sufficient quality 
control, or about the risks of the specific drugs that are being used, they 
cannot conduct rigorous independent scrutiny of lethal injection 
research. This secrecy has been justified based on concerns that death 
penalty opponents will protest or harass those involved with executions, 
but makes it difficult to feel confident that courts are providing sufficient 
oversight.240 
Another possibility, as discussed in Part III above, would be for the 
FDA to review executions by lethal injection. Under the FDA 
238. See, e.g., Jack Schwartz, The Kennedy Krieger Case: Judicial Anger and the Research 
Enterprise, 6 J. HEALTH CARE L. & POL’Y 148, 152–53 (citing Grimes v. Kennedy Krieger Inst., 
Inc., 782 A.2d 807 (Md. 2001)).  
239. See generally Transcript of Telephonic Motion for Emergency Stay of Execution, Wood v. 
Ryan, No. CV 14-1447-PHX-NVW (D. Ariz. July 23, 2014), available at http://www.scribd.com/ 
doc/234993495/Transcript-related-to-Joseph-Wood-execution. 
240. Michael Graczyk, Texas Agency Pushes to Keep Execution Drug Source Secret, NEWSOK 
(Apr. 2, 2014), http://newsok.com/texas-pushes-to-keep-execution-drug-source-secret/article/3949442. 
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regulations, the FDA would review an IND application and would 
require that an IRB review the research at the same time.241 The FDA 
may be reluctant to review executions, particularly without a clear sense 
of what risk standard to apply. Unlike the courts, however, the FDA has 
expertise in reviewing research, medical practice, and non-validated uses 
of drugs and devices. The FDA has considerable scientific expertise and 
is likely to be the body that is best informed about how the drugs being 
used for lethal injection work and what risks are associated with them. It 
is likely that the depth of expertise available at the FDA far surpasses 
what an individual court can bring to bear on the questions surrounding 
lethal injection. The FDA might be well situated to review lethal 
injection experimentation. 
Finally, it is possible that special institutional bodies could be set up 
to review the quality control activities of various prisons. This approach 
has the advantage of ensuring that people who have the relevant 
expertise would be the ones reviewing the activities. Such a board might 
include scientists who conduct research, former prisoners, lawyers, and 
ethicists. One concern about this board is that it might be subject to 
capture by advocates from either side of the death penalty debate. It 
might therefore be advisable that some independent institution, such as 
the judicial branch, be involved in vetting the board members, 
analogously to the judicial use and oversight of special masters in 
consent decrees.242 
Given the special expertise, authority, and independence of the FDA, 
it seems clear that the FDA is at this time best positioned to review 
experimentation in executions by lethal injection. A specially constituted 
institutional board that has relevant expertise may be an alternative or an 
addition to FDA review. 
B. Minimizing Risk 
Both research and quality control activities are subject to the 
requirement to minimize risk. Judging the risk level of research on 
methods of execution by lethal injection requires comparing an 
241. 21 C.F.R. § 312.66 (2014). 
242. Wayne D. Brazil, Special Masters in Complex Cases: Extending the Judiciary or Reshaping 
Adjudication?, 53 U. CHI. L. REV. 394, 394–95 (1986) (“Courts appoint special masters as a means 
of addressing three overlapping categories of problems: judicial limitations, shortcomings of the 
traditional adjudicatory system, and shortcomings of parties and counsel. Judicial limitations 
include time constraints; lack of expertise in esoteric or technologically sophisticated areas; lack of 
skill in certain roles, such as the facilitation of settlement negotiations; and limitations that stem 
from the proprieties of judicial conduct, at least for the judge who will try the case.”). 
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experimental execution to a standard execution. The risk of death is 
therefore not a risk of the research—death is actually, in this case, the 
desired outcome. The benefits might have to do with having shorter 
executions that are more likely to be humane (perhaps analogous to the 
benefits in palliative care research conducted at the end of life). Those 
individuals who are being experimented upon should not be exposed to 
any unnecessary risk that could easily be eliminated. The risk that seems 
most relevant in analyzing executions by lethal injection is the risk of 
pain and suffering before death, both in terms of its severity and its 
duration. In other words, a long, drawn-out execution with significant 
pain might be as concerning as a shorter execution that subjected an 
inmate to pain of greater intensity. 
In the case of In re Kemmler, the Court clarified that to violate the 
Eighth Amendment, there must be “something inhuman and barbarous, 
something more than the mere extinguishment of life.”243 Although it is 
clear that torture is beyond the pale, what degree of risk of a torturous 
death the Eighth Amendment will tolerate is an open question. The 
standards for weighing acceptable risks in research are similar, in some 
respects, to the approach the Supreme Court has taken in defining what 
risks of pain and suffering would be unconstitutional. As the Court 
explained in Francis v. Resweber,244 “The traditional humanity of 
modern Anglo-American law forbids the infliction of unnecessary pain 
in the execution of the death sentence. Prohibition against the wanton 
infliction of pain has come into our law from the Bill of Rights of 1688. 
The identical words appear in our Eighth Amendment.”245 It has also 
been recognized that an Eighth Amendment analysis requires analyzing 
the objective risk of harm, and if that risk is significant enough, prison 
officials cannot claim that they were “subjectively blameless” for harm 
that would otherwise violate the Eighth Amendment.246 
However, how a court should weigh the objective risk of harm 
became somewhat muddied in Baze v. Rees. There, a plurality of the 
Court noted that the Supreme Court has shied away from providing a 
precise definition of the Eight Amendment’s prohibition on cruel and 
unusual punishment. The plurality approvingly quoted a case from 1879, 
which noted that difficulty would attend the effort to define “with 
exactness the extent of the constitutional provision which provides that 
243. 136 U.S. 436, 447 (1890). 
244. Louisiana ex rel. Francis v. Resweber, 329 U.S. 459 (1947). 
245. Id. at 463. 
246. Farmer v. Brennan, 511 U.S. 825, 842, 846 n.9 (1994). 
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cruel and unusual punishments shall not be inflicted;” but “it is safe to 
affirm that punishments of torture, . . . and all others in the same line of 
unnecessary cruelty, are forbidden” by that amendment to the 
Constitution.247 As Deborah Denno has argued, “the Court lacks a 
coherent constitutional standard for assessing pain. Although the 
gratuitous infliction of pain is definitely impermissible, far less clear is 
the constitutionally allowable amount of pain that can exist for an 
execution and the penological theory that might justify such pain.”248 
In Baze, the different opinions argued for different standards: (1) the 
plurality indicated that a lethal injection protocol is not “cruel and 
unusual” unless it involves a “substantial risk of serious harm” or an 
“objectively intolerable risk of harm” and there are alternatives that 
effectively address this risk;249 (2) Justice Thomas argued that 
executions violate the Eighth Amendment only when protocols are 
“deliberately designed to inflict the pain”—thereby arguing for a focus 
only on the subjective prong of an Eighth Amendment analysis; and (3) 
Justice Ginsburg’s dissent (joined by Justice Souter) argued for a 
standard that rules out an “untoward, readily avoidable risk of inflicting 
severe and unnecessary pain.”250 Justice Ginsburg’s dissent requiring 
that there be no “untoward risk”251 was the only standard that was 
consistent with the obligation to minimize risks in research or quality 
control activities. Thirty-six cases have cited Justice Ginsburg’s dissent 
in an attempt to establish that, even under the strictest standard laid out 
in Baze, the protocol in question would be considered constitutional.252 
Noting the Court’s inability to agree on a particular standard, as well as 
the considerable changes that have been made to lethal injection 
protocols (even the Kentucky protocol approved in Baze has been 
changed to a one-drug protocol), Denno has argued that the precedent set 
in Baze is largely moot.253 
Practically, risk minimization likely puts extra scrutiny on particular 
aspects of execution by lethal injection. For instance, risk minimization 
may require Departments of Corrections to stop using the drug 
247. Baze v. Rees, 553 U.S. 35, 48 (2008) (quoting Wilkerson v. Utah, 99 U.S. 130, 136 (1879)). 
248. Deborah W. Denno, Getting to Death: Are Executions Constitutional?, 82 IOWA L. REV. 
319, 326 (1997). 
249. Baze, 553 U.S. at 50, 52. 
250. Id. at 52 (plurality opinion); id. at 94 (Thomas, J., concurring); id. at 123 (Ginsburg, J., 
dissenting). 
251. Id. at 123 (Ginsburg, J., dissenting). 
252. Denno, supra note 27, at 1353. 
253. Id. at 1346. 
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midazolam (which was implicated in three of the four botched 
executions that occurred in 2014),254 intramuscular injections, paralytic 
agents, and compounding pharmacies. Additionally, securing the 
involvement of physicians would be an important way to minimize the 
risks to which inmates are exposed. 
Some state protocols permit intramuscular injection, which is also 
unnecessarily risky.255 Individuals who receive intramuscular injections 
may experience wide variation in how quickly the drug is taken up by 
their bodies, and may therefore suffer extended executions and increased 
exposure to painful side effects.256 Given the possibility of faster-acting 
intravenous injection, this risk may not be necessary. The use of 
compounding pharmacies adds to the risk, since it is possible that 
incorrect drugs or dosages will be used, or that the drugs will be 
contaminated. Finally, despite the controversy it would raise, it seems 
likely that the involvement of medically trained professionals may also 
decrease the risks associated with lethal injection.257 
The use of paralytic agents fails scrutiny under a standard requiring 
254. See Missouri Used Controversial Execution Drug Midazolam, Report Finds, THE 
GUARDIAN (Sept. 3, 2014, 4:15 PM), http://www.theguardian.com/world/2014/sep/03/missouri-
execution-drug-sedative-midazolam-report. 
255. See, e.g., STATE OF OHIO DEP’T OF REHAB. & CORR., supra note 168. 
256. Declaration of Mark J.S. Heath, M.D. at 6–9, Cooey (Biros) v. Strickland, No. 2:04cv1156-
GLF-MRA (S.D. Ohio. Dec. 3, 2009). 
257. The American Medical Association has an ethical prohibition on physician involvement in 
executions, and there is considerable debate over whether physicians should participate in 
executions by lethal injection in the scholarly literature. See, e.g., AM. MED. ASS’N, CODE OF 
ETHICS OPINION 2.06 – CAPITAL PUNISHMENT (2005); Ty Alper, The Role of State Medical Boards 
in Regulating Physician Participation in Executions, 95 J. MED. LICENSURE & DISCIPLINE (2009), 
available at http://papers.ssrn.com/sol3/papers.cfm?abstract_id=1544623; Linda L. Emanuel, 
Letter: Physicians and Executions, HASTINGS CTR. REP. Mar.–Apr. 2012, at 4; Lawrence Nelson & 
Brandon Ashby, Rethinking the Ethics of Physician Participation in Lethal Injection Execution, 
HASTINGS CTR. REP., May–June 2011, at 28, 29; Robert D. Truog & Troyen A. Brennan, 
Participation of Physicians in Capital Punishment, 329 NEW ENG. J. MED. 1346, 1348 (1993); 
Robert D. Truog, I. Glenn Cohen, & Mark A. Rockoff, Physicians, Medical Ethics, and Execution 
by Lethal Injection, 311 J. AM. MED. ASS’N 2375 (2014); Robert M. Veatch, The Impossibility of a 
Morality Internal to Medicine, 26 J. MED. & PHIL. 621, 634 (2001); David Waisel, Physician 
Participation in Capital Punishment, 82 MAYO CLINIC PROC. 1073, 1079 (2007). Notwithstanding 
this debate, some physicians clearly do participate in executions without fear of legal sanction. See, 
e.g., Ty Alper, The Role of State Medical Boards in Regulating Physician Participation in 
Executions, 95 J. MED. LICENSURE & DISCIPLINE 1, 3 (2008) (noting that states have indicated that 
physicians were involved in overseeing executions and have even taken more active roles, and that 
legal prohibitions are unlikely to be enforced); Denno, supra note 99, at 65–70 (explaining that 
physicians have been involved in executions since the creation of the first lethal injection protocol 
in Oklahoma); Atul Gawande, When Law and Ethics Collide—Why Physicians Participate in 
Executions, 354 NEW ENG. J. MED. 1221, 1223–28 (2006) (interviewing physicians who indicated 
that they have participated in executions for various reasons). 
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risk minimization. These agents mask any movements or distress by the 
inmate, making it impossible to tell if the inmate has not been properly 
anesthetized. The justification for a paralytic agent is to further the 
state’s interest in dignity by maintaining an appearance of a peaceful 
death. Although the state might have some reason to modify executions 
to make them seem more dignified, there should be a limit on the level 
of risk involved. For instance, the use of blankets to cover an inmate’s 
limbs might be one way a state could make an execution appear more 
dignified without increasing risk. On the other hand, if a state were to 
argue that having to submit to lethal injection challenges in the courts 
and share information about executions publicly limits the dignity of the 
procedure, this would seem to give the interest in dignity far too much 
weight. Because it could pose significant risk, the use of a paralytic 
agent does not seem justifiable by an interest in dignity, and therefore 
fails to fulfill the obligation to minimize risks in research. 
C. Informed Consent 
Another requirement for the ethical conduct of research is informed 
consent. Valid informed consent would require disclosure of the drugs 
and procedures being used, the risks involved, and the available 
alternatives. Obtaining informed consent helps ensure that people are not 
subjected to experimentation unknowingly or against their will and that 
they are able to protect their own interests.258 Asking for informed 
consent from inmates could also help ensure that lethal injection 
protocols are not excessively risky for particular inmates with special 
conditions. For instance, Russell Bucklew’s execution has been placed 
on hold by the Supreme Court because he has a unique medical 
condition, referred to as cavernous hemangioma, which causes him to 
have clumps of malformed blood vessels that would greatly increase the 
risks of a prolonged and painful execution.259 
As the Institute of Medicine’s Committee on Ethical Considerations 
for Protection of Prisoners Involved in Research stated, “ethical research 
involves ensuring, as a prerequisite for research, that the standard of 
medical health care available in the correctional setting permits the 
inmate to have a meaningful choice between the existing care that is 
available and the experimental intervention.”260 Inmates do not, of 
258. Emanuel, Wendler & Grady, supra note 233, at 2706. 
259. John Eligon, Supreme Court Halts Missouri Execution and Sends Case Back to Appeals 
Court, N.Y. TIMES, May 22, 2014, at A16.  
260. ETHICAL CONSIDERATIONS, supra note 93, at 22. 
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course, have the right to give informed consent to being executed—that 
decision is for a jury to make. Instead, just as some inmates might be 
given a choice to participate in research conducted by the state testing a 
new medication for treating HIV, so too should inmates be asked for 
their consent to participate in research about how they should be killed. 
As previously discussed, consent is required for quality control 
procedures that involve more than minimal risk, and is typically required 
for many categories of research. 
States seeking to modify their lethal injection protocols would have to 
ask inmates whether they prefer the modified or unmodified version of 
the protocol or could offer inmates a choice of a different method of 
execution altogether. This is not a wholly unprecedented suggestion. 
Great Britain’s Royal Commission on Capital Punishment reviewed 
lethal injection in the middle of the twentieth century and noted that, 
although lethal injection raised too many concerns for them to 
recommend its immediate adoption, an anesthetist testifying before the 
Royal Commission suggested that: “It should be offered as an 
alternative, pleasanter, method of execution, and should be used only 
when it has been willingly accepted.”261 The Royal Commission was 
concerned that inmates might have a hard time making such a decision, 
and also believed that it was the State’s responsibility to select the best 
method of execution available and carry it out with “dignity, solemnity, 
speed, and certainty.”262 
Nevertheless, some states do offer inmates a choice between different 
methods of execution. Florida’s statute provides that a person sentenced 
to death will undergo lethal injection, unless he or she “affirmatively 
elects to be executed by electrocution.”263 Missouri permits execution 
261. ROYAL COMM’N ON CAPITAL PUNISHMENT, supra note 124, at 259. 
262. Id. 
263. FLA. STAT. § 922.105(1) (West, Westlaw through Ch. 255 (End) of 2014 2d Reg. Sess. & 
Sp. “A” Sess. of 23d legislature); see also South Carolina: “A person convicted of a capital crime 
and having imposed upon him the sentence of death shall suffer the penalty by electrocution or, at 
the election of the person, lethal injection under the direction of the Director of the Department of 
Corrections. The election for death by electrocution or lethal injection must be made in writing 
fourteen days before the execution date or it is waived. If the person waives the right of election, 
then the penalty must be administered by lethal injection.” S.C. CODE ANN. § 24-3-530(A) 
(Westlaw through end of 2014 Reg. Sess.); Tennessee: noting that if other methods become 
unavailable for some reason, an inmate no longer has the right to choose and “all persons sentenced 
to death for a capital crime shall be executed by any constitutional method of execution,” TENN. 
CODE ANN. § 40-23-114 (Westlaw through end of 2014 2d Reg. Sess.); Utah: allowing some 
inmates to opt for death by firing squad, UTAH CODE ANN. § 77-18-5.5 (Westlaw through 2014 
General Sess.); Virginia: “The Director, or the assistants appointed by him, shall at the time named 
in the sentence, unless a suspension of execution is ordered, cause the prisoner under sentence of 
death to be electrocuted or injected with a lethal substance, until he is dead. The method of 
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either by lethal injection or in a gas chamber.264 By contrast, in twenty-
one states, lethal injection is the only execution method allowed.265 
Some states could reinstate older methods of execution to offer 
alternatives.266 Of course, alternative approaches to execution may not 
be available if they have been ruled unconstitutional, so the only 
alternative in such jurisdictions would be an unmodified lethal injection 
protocol.267 If there are states where there are truly no alternative 
options, it may still be worthwhile to provide inmates with the 
information about the protocol to see if there are any particular risks that 
can be minimized—for instance, if a larger dose of the anesthetic might 
be needed for an inmate who previously suffered from drug addiction. 
Simply informing inmates about what they will be given may be an 
important protection for inmates who have special medical conditions 
that make the planned doses or drugs especially risky for them.268 
Significantly, inmates are likely to give consent to at least some 
execution shall be chosen by the prisoner. In the event the prisoner refuses to make a choice at least 
fifteen days prior to the scheduled execution, the method of execution shall be by lethal injection. 
Execution by lethal injection shall be permitted in accordance with procedures developed by the 
Department.” VA. CODE ANN. § 53.1-234 (Westlaw through end of 2014 Reg. Sess. & includes cc. 
1 to 5 from the 2014 Sp. S. I.); Washington: “The punishment of death shall be supervised by the 
superintendent of the penitentiary and shall be inflicted by intravenous injection of a substance or 
substances in a lethal quantity sufficient to cause death and until the defendant is dead, or, at the 
election of the defendant, by hanging by the neck until the defendant is dead. In any case, death 
shall be pronounced by a licensed physician.” WASH. REV. CODE § 10.95.180(1) (2014). 
264. MO. REV. STAT. § 546.720(1) (Westlaw through end of 2014 2d Reg. Sess. of 97th General 
Assembly). In an analysis of different methods of execution conducted in the mid-twentieth century, 
Great Britain’s Royal Commission on Capital Punishment dismissed lethal gas as an option because 
of the “highly unpleasant historical associations” with lethal gas that might render this method of 
execution unpalatable to the public. ROYAL COMM’N ON CAPITAL PUNISHMENT, supra note 124, at 
257.  
265. Denno, supra note 27, at 1342 (current information as of June 2014). See, e.g., KY. STAT. 
ANN. § 431.220(1)(a) (Westlaw through end of 2014 legis.) (“every death sentence shall be 
executed by continuous intravenous injection of a substance or combination of substances sufficient 
to cause death”).  
266. David Stout, The Tennessee Senate Has Backed a Bill to Reinstate the Electric Chair, TIME 
(Apr. 10, 2014), http://time.com/57066/tennessee-senate-electric-chair-capital-punishment-
execution/. 
267. For instance, the Ninth Circuit has ruled that gas chamber executions are unconstitutional. 
See Fierro v. Gomez, 77 F.3d 301, 309 (9th Cir. 1996). 
268. See, e.g., Bucklew v. Lombardi, 565 F. App’x 562, 564 (8th Cir. 2014) (Granting a stay of 
execution after agreeing that the evidence demonstrated that Bucklew “suffers a medical condition 
known as cavernous hemangioma involving large vascular deformities and tumors in his face and 
neck that cause pressure, pain, and frequent bleeding” that was likely to result in “either (1) a long, 
drawn-out, and painful death due to poor movement of the drug through his atypical circulatory 
system, or (2) death via choking and suffocation on blood released by anticipated ruptures of the 
weakened veins in his neck and face.”); stay subsequently granted in Bucklew v. Lombardi, 
__ U.S __, 134 S. Ct. 2333 (2014). 
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protocols. Ohio’s brief move to a one-drug protocol was what inmates 
had been requesting in prior litigation because it was likely to decrease 
risks.269 
There is, however, an important issue to resolve in obtaining informed 
consent for executions. Under Stewart v. LeGrand,270 the Supreme Court 
held that if an inmate elects a particular method of execution, he waives 
his right to challenge its constitutionality.271 In the canons of research 
ethics, the function of requiring informed consent in research is to ensure 
that individuals can protect their own interests and exercise their 
autonomy.272 The FDA regulations and the DHHS regulations indicate 
that informed consent cannot serve as a waiver, stating as follows: “No 
informed consent, whether oral or written, may include any exculpatory 
language through which the subject or the representative is made to 
waive or appear to waive any of the subject’s legal rights, or releases or 
appears to release the investigator, the sponsor, the institution or its 
agents from liability for negligence.”273 
In the lethal injection context, informed consent can help ensure that 
the options that minimize risks are offered to inmates, the changes made 
to protocols do not increase the risks, and that inmates with particular 
conditions that increase the risks are identified in advance. These 
protective functions could be watered down if inmates were wary of 
electing one option over another because it foreclosed future legal 
challenges. Given the state of flux in lethal injection protocols, it also 
seems important to preserve an ongoing right to challenge a protocol 
when evidence emerges about new risks or better alternatives. 
Inmates would have to be informed what drugs were being used in the 
modified and unmodified protocols to make an informed choice. That 
disclosure would violate the secrecy some states now maintain. Much of 
the experimentation being conducted is not transparent. A Texas 
appellate court recently permitted the Department of Corrections to keep 
secret the name of the compounding pharmacy producing the drugs they 
will use in an upcoming execution.274 The court reasoned that revealing 
269. See generally State v. Rivera, Nos. 04CR065940, 05CR068067 (Ohio Cnty. Ct. C.P. June 
10, 2008). 
270. 526 U.S. 115 (1999). 
271. Id. at 119 (1999); see also State v. Morris, 24 S.W.3d 788, 797 (Tenn. 2000). 
272. Ezekiel J. Emanuel, David Wendler, & Christine Grady, What Makes Clinical Research 
Ethical?, 283 J. AM. MED. ASS’N 2701, 2706 (2000). 
273. 21 C.F.R. § 50.20 (2014); 45 C.F.R. § 46.116 (2014) (general requirements for informed 
consent). 
274. Michael Graczyk, Appeals Court: Texas Execution Back On, BIG STORY (Apr. 7, 2014), 
http://bigstory.ap.org/article/appeals-court-texas-execution-back. 
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the names of these pharmacies subjects them to pressure and protests 
from anti-death penalty groups. One Associated Press investigation 
found that all but four states refused to disclose the source of their lethal 
injection drugs.275 Thus, informed consent is an important protection that 
many states could easily incorporate, but that is incompatible with the 
level of secrecy in some states. 
CONCLUSION 
By using new drugs, novel drug combinations, and untested doses, 
executions by lethal injection involve medical experimentation that is 
neither well designed nor evidence based. Executions have not adhered 
to the standards of validating medical practice, which would require 
careful extrapolation from existing data and/or rigorous data gathering in 
humans to find an effective approach that does not exceed the Eighth 
Amendment’s restrictions on risks of pain and suffering. States have also 
failed to take account of the principles and legal requirements governing 
biomedical research, including obtaining independent review, informed 
consent, and minimizing risks. Adherence to those principles would 
protect inmates against excessive and unnecessary risks. 
Some readers may be concerned that these arguments are merely a 
cover for an abolitionist view on the death penalty. Because certain 
lethal injection drugs are in short supply, adherence to the principles of 
biomedical research may be very difficult. The logical conclusion might 
be to halt executions by lethal injection. While it is possible that 
abolitionists will find some of the arguments made here congenial to 
their views, it is also possible that this Article provides a framework for 
more humane lethal injections that may be more acceptable to courts and 
the general public. The goal of this paper is not to spell out better ways 
to perform lethal injection, but to make clear how to understand lethal 
injection experimentation and how to regulate it. In particular, this 
analysis may help ensure that the current practice of lethal injection is 
properly regulated so that it no longer involves scientifically 
questionable, disrespectful, and risky experimentation on inmates. Death 
penalty proponents have shown resourcefulness in responding to lethal 
injection challenges,276 as have abolitionists,277 and it would be 
275. Andrew Welsh-Huggins & Jim Salter, In Most States, Execution Drugs Are Surrounded By 
Secrecy, HUFFINGTON POST (Apr. 5, 2014), http://www.huffingtonpost.com/2014/04/05/execution-
drugs-secrecy_n_5097069.html. 
276. Mark Berman, Missouri Attorney General Wants the State to Produce its Own Lethal 
Injection Drugs, WASH. POST (May 29, 2014), http://www.washingtonpost.com/news/post-nation/ 
wp/2014/05/29/missouri-attorney-general-wants-the-state-to-produce-its-own-lethal-injection-drugs. 
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overstating the case to imagine that this Article could end the debate 
over executions by lethal injection one way or the other. 
It is possible that challenges to lethal injection will push states to 
revert to other methods of execution that have been used in the past, 
including firing squads, hanging, electrocution, and lethal gas. Many of 
these options raise concerns beyond the scope of the present paper.278 
However, it is worth noting that the FDA regulates the use of anesthetic 
gas, and it is sometimes used as a medical intervention.279 For this 
reason, the use of the gas chamber may be subject to FDA oversight and 
might face challenges similar to those I have discussed here. 
Future research on experimental executions should address what 
causes of action might be available to prisoners to challenge lethal 
injection executions as involving the conduct of research. Other 
questions include whether families of inmates in executions gone wrong 
can obtain damages from the state—and whether alternatives like the use 
of lethal gas might raise similar concerns about the conduct of research. 
My analysis has also revealed gaps in research ethics and regulation. 
Many scholars have noted that there are significant gaps in the 
regulation of research in the absence of federal funding.280 Less explored 
are gaps in regulation of poorly conducted and secretive research. If 
biomedical research is systematic and rigorous, it should clearly be 
regulated. If, however, biomedical research is poorly designed and 
In addition, proposals for a new method have sometimes come from unusual quarters. See Tracy 
Connor, Jack Kevorkian’s Aide Pushed Carbon Monoxide for Executions, NBC NEWS (May 29, 
2014, 11:36 AM), http://www.nbcnews.com/storyline/lethal-injection/jack-kevorkians-aide-pushed-
carbon-monoxide-executions-n117806. 
277. Holly Williams, Meet the Woman Behind a Shortage of Execution Drugs, CBS NEWS, (Apr. 
30, 2014, 7:31 PM), http://www.cbsnews.com/news/meet-the-woman-behind-a-shortage-of-
execution-drugs/.  
278. See Robert J. Sech, Hang ‘Em High: A Proposal for Thoroughly Evaluating the 
Constitutionality of Execution Methods, 30 VAL. U.L. REV. 381 (1995). See generally Christopher 
Q. Cutler, Nothing Less than the Dignity of Man: Evolving Standards, Botched Executions and 
Utah’s Controversial Use of the Firing Squad, 50 CLEV. ST. L. REV. 335 (2003). Chief Judge 
Kozinski has argued that lethal injection is a flawed enterprise because it attempts to mask the fact 
that executions “are brutal, savage events, and nothing the state tries to do can mask that reality. Nor 
should it. If we as a society want to carry out executions, we should be willing to face the fact that 
the state is committing a horrendous brutality on our behalf.” Wood v. Ryan, 759 F.3d 1076, 1103 
(9th Cir. 2014) (Kozinski, J., dissenting). He ultimately settled on the firing squad as the most 
promising method of execution, and states: “If we, as a society, cannot stomach the splatter from an 
execution carried out by firing squad, then we shouldn’t be carrying out executions at all.” Id.  
279. See Bazter Int’l, Inc. v. Abbott Labs., 315 F.3d 829, 830 (7th Cir. 2003). 
280. Deborah A. Zarin et al., Federal Human Research Oversight of Clinical Trials in the United 
States, 311 J. AM. MED. ASS’N 960, 960 (2014) (finding that between five to sixteen percent of 
clinical trials may fall into this regulatory gap). 
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cloaked in secrecy, it becomes much more difficult to determine how to 
regulate it, and even the avenues suggested here may depend on 
voluntary action by an agency like the FDA. This regulatory gap exists 
even though concerns about risks and uncertainty might increase in 
research that is not well designed, evidence-based, conducted by experts, 
or transparent. The origins of and solution to this paradox of research 
ethics and regulation are critically important avenues for future research. 
 
 
